REVIEW

Recent advances and developments in the antitumor effect of the HVJ envelope vector on malignant melanoma: from the bench to clinical application

A Tanemura[1], E Kiyohara[1,2], I Katayama[1] and Y Kaneda[2]

Inactivated Sendai virus particles (hemagglutinating virus of Japan envelope; HVJ-E) are considered to be safe and efficient non-viral vectors used for drug delivery, since they can incorporate DNA, RNA, proteins and drugs. We have recently found that HVJ-E has a novel antitumor immune effect using a colon cancer model. HVJ-E has also been shown to have both direct and immune-mediated indirect actions against malignancy. Intratumoral injection of an inactivated HVJ-E solution significantly reduced the tumor volume and prevented spontaneous lung metastasis, leading to an increased overall survival in C57/BL6 mice transplanted with B16/BL6 mouse melanoma cells, and even in immunodeficient mice transplanted with Mewo human melanoma cells. No severe adverse effects including laboratory data abnormalities or anaphylactic reactions were observed. The comprehensive mechanism(s) underlying the immunological effects of HVJ-E appear to include not only enhanced effector T cell- and/or natural killer (NK) cell-mediated immunity, but also rescue from regulatory T cell (Treg)-mediated immunosuppression, presumably through the interleukin-6 secretion from dendritic cells stimulated by HVJ-E. Since a protocol for a clinical study of HVJ-E in malignant melanoma was approved in 2009 by the ethics committee of Osaka University and of the Medical Center for Translational Research in Osaka University Hospital, a phase I/IIa study for advanced malignant melanoma patients was just started. In this review, we show several favorable results regarding the antitumor effects of HVJ-E and describe the novel mechanism underlying this tumor immune response. Since we are conducting a phase I/IIa clinical trial using HVJ-E in advanced melanoma patients on the basis of preclinical results, detailed clinical information and immune-monitoring data are also introduced. The development of new therapeutic modalities for advanced melanoma patients is urgently needed, and we hope that HVJ-E may provide one such treatment.

INTRODUCTION

Malignant melanoma is a highly aggressive malignancy that is resistant to most treatment. Although standard biochemo-therapy including dacarbazine and cisplatin, as well as granulocyte macrophage colony-stimulating factor for the activation and maturation of dendritic cells (DCs), has been established for melanoma patients, the response rate is insufficient, at <25% for advanced malignant melanoma.[1,2] In addition, although many immunotherapies for advanced stage melanoma patients have been evaluated on the basis of their high immunogenic potential, these have generally failed,[3–6] partly because the tumor-specific damage is prevented by a loss of specific antigens caused by the genetic mutation of tumor cells or by the disappearance of human leukocyte antigen-related molecules. Therefore, it is indispensable to look for a novel immunogenic approach that can regulate melanoma growth and metastasis.

Although the transplantation of melanoma antigen-specific T-cell receptor-carrying cytotoxic T lymphocytes (CTLs) can directly attack melanoma cells, the antitumor effect is limited and attenuated because of the deletion of human leukocyte antigen expression and the loss of several inhibitory factors, such as regulatory T cell (Treg) and monocyte-derived suppressor cells via interleukin-10

(IL-10) and transforming growth factor β production. On the other hand, with respect to the examination of direct placement of a tumor antigen genetically modified virus, an antitumor effect was obtained based on a specific immune reaction for a case that was administered a high dosage of IL-2 after immunization with a recombinant fowlpox virus, which was designed to effectively show T-cell epitopes.[7,8] Recently, immunomodulation therapy by adoptive cell transfer of autologous tumor-infiltrating lymphocytes, combined with preceding myelo- or lympho-depletion and subsequent IL-2 administration, was introduced for patients with metastatic solid cancer patients,[9] and the objective response rate was reported to be >50% in a clinical trial in stage IV melanoma patients.[10]

It is well known that the humanized anti-CTLA-4 (cytotoxic T-lymphocyte antigen 4) antibody, named ipilimumab, which can overcome the negative feedback effect in DCs, was approved by the federal drug and food in 2011 because it provided a significant improvement in the overall survival compared with vaccine therapy using the gp100 peptide.[11] Moreover, the anti-PD-1 (programmed cell death-1) or PD-L1 antibody that restores T-cell inhibition by the PD-L1–CD28 interaction is becoming one of effective tools used for advanced melanoma with regard to immune modulation.[12]

Since about 2005, basic and clinical efforts to improve anticancer immunotherapy have shed light on what is needed for sufficient therapy for malignant melanoma.[9-12] Among these promising results in immunotherapy, we have recently shown an augmentation of antitumor immunity and tumor cell death induction by a hemagglutinating virus of Japan envelope (HVJ-E) vector for several carcinomas.[13-16] HVJ, which belongs to Paramyxovirus family of Paramyxoviridae genus, was originally reported by Ishida et al. in 1953.[17] Inactivated HVJ particles have been useful as a drug delivery system based upon their high cell-fusion affinity and ability to deliver DNA, RNA and proteins components.[18] On another front, we have shown and reviewed that HVJ-E has the potential to comprehensively improve the antitumor immunity by performed detailed in vitro and in vivo analyses.[14-16] In this review, we would like to describe our recent experimental data demonstrating the antitumor effects of HVJ-E in malignant melanoma in vivo and introduce the entry information about our first-in-man clinical trial.

The development of HVJ-E

HVJ-E is derived from an inactivated Z strain of HVJ produced from fertilized chicken eggs or human cells cultured in non-serum. Clinical grade HVJ-E is manufactured through the inactivation of cell-derived HVJ with an alkylating agent (β-propiolactone) and ultraviolet irradiation, purification processing by column chromatography and formulation processing by freeze dying. The structure of HVJ-E, as shown in the frame format of Figure 1, is a nanoparticle measuring ~230 nanometers in diameter with an outer membrane, and comprises protein, glycoprotein, a lipid bilayer and residual nucleic acids. HVJ belongs to the Paramyxovirus family of Paramyxoviridae, which also causes parainfluenza in mice. Following the publication of the report by Ishida et al. in 1953,[17] HVJ is otherwise known as the 'Sendai Virus.' Although HVJ is a potential cause of pneumonia in mice, it is not pathogenic in humans due to specific differences in the host enzymes that are necessary to acquire infection.

HVJ is unique in that it demonstrates cell fusion activity through the functions of the F protein and the HN protein that exist in the outer membrane. This phenomenon was reported by Okada et al. 1957, based on the results of a study using a Z strain of HVJ[17] which subsequently led to the invention of monoclonal antibodies taking advantage of this property,[19] along with the production of chromosome maps.[20] Furthermore, inactivated HVJ particles (HVJ-E) are being used as a raw material for the delivery of macromolecular substances, by taking advantage of their membrane fusion activity. HVJ is also being developed as a drug delivery system, known as HVJ liposome or HVJ-E, which provided good results in animal experiments.[21,22]

Activation of antitumor immunity by HVJ-E

In recent years, it has been clarified that HVJ-E itself has an antitumor effect[16] against mouse colon carcinoma cell lines subcutaneously transplanted onto the backs of mice. When three doses of 1.5×10^{10} of HVJ-E were administered intratumorally following the development of 5 mm tumors, the growth of the tumors was inhibited compared with mice treated with an adenovirus deactivated by saline or ultraviolet rays in a similar manner. Furthermore, when other cells were transplanted onto the contralateral side of the back of these mice after 4 days, tumor formation was completely prevented in three out of five mice. In other words, HVJ-E treatment also decreased the formation of a new tumor and maintained the antitumor immune reaction, in addition to growth inhibition properties. Furthermore, an analysis of the infiltration of immune-competent cells into the tumor cells was performed. When the CD11c expression was investigated using quantitative RT-PCR to assess the DC infiltration, there were higher levels 24 and 48 h after injection compared with the control


Figure 1. The structure of live hemagglutinating virus of Japan (HVJ). A nucleocapsid containing ~15 kb of the single-stranded viral RNA genome and nucleocapsid protein (NP), as well as polymerases P and L, is located inside, and the F and N proteins penetrating the envelope are associated with cell fusion. Live HVJ becomes the non-amplifying inactive form (HVJ-E; HVJ-envelope) following treatment with ultraviolet radiation or an alkylating agent.

group, and the expression was sustained even after 120 h. As the tumor tissue treated with HVJ-E was found to have increased expression of CD40, CD80 and CD86, which are surface markers indicating the maturation of DCs, it was suggested that mature DCs infiltrated into the tumor tissues injected with HVJ-E (Figure 2a).

Second, a significantly larger number of tumor-infiltrating CD4- and CD8-positive T lymphocytes were observed 48 h after the three consecutive doses of HVJ-E in some of the tumors, indicating the induction of tumor-specific CTLs, which was augmented by HVJ-E (Figure 2b). In fact, systemic activation of CTLs against melanoma was obtained in mice injected with HVJ-E when splenocytes were used for the chrome-release assay in colon cancer cell-bearing mice.[16] On the basis of these results and our previous publications,[14-16,23] it can be concluded that HVJ-E itself has antitumor effects through the activation of CTLs against tumors. For more detailed information about the mechanisms underlying the antitumor effects of intratumoral HVJ-E injection, please see Kaneda,[14,15] Kurooka and Kaneda[16] and Fujiwara et al.[23]

Regulatory T cells (hereafter referred to as 'Tregs') have been pointed to inhibit antitumor immunity, with great importance now being placed on how the inhibitory effects of Tregs can be avoided. IL-6 has been reported to be an important cytokine involved in controlling the function and differentiation of Tregs.[24,25] For this reason, we examined whether HVJ-E acted on DCs to accelerate the secretion of IL-6. It was found that HVJ-E acted on DCs to promote them to secrete IL-6 in an amount equivalent to that produced in response to live HVJ. On the other hand, only a small amount of tumor necrosis factor α was secreted following HVJ-E treatment, and while IL-12 was secreted in large amounts in response to adenoviruses, the amount was very small for both HVJ-E and live HVJ virus (Figure 2c).

On the basis of these findings, it was assumed that only IL-6 was secreted in large amounts from DCs by the inactivated HVJ, and that HVJ-E suppressed the function of Tregs via the secretion of IL-6 from DCs, because IL-6 is known to suppress FoxP3 (a transcription factor required by Tregs) expression in DCs.[26] It was also examined whether such production of IL-6 by DCs was in fact happening in vivo after the administration of the HVJ-E vector. When CD11c-positive cells were collected from both tumor and

Figure 2. Immunoactivation in the tumor-bearing mice after the treatment with hemagglutinating virus of Japan envelope (HVJ-E). (a) The expression of the maturation markers of dendritic cells (DCs) was increased in the implanted tumors after the injection with HVJ. Lipopolysaccharide (LPS) and phosphate-buffered saline (PBS) were used as positive and negative controls, respectively. Solid, blank, longitudinal striped and dotted columns indicate the percentages of DCs positive for each maturation marker after the treatment with HVJ, HVJ-E, LPS and PBS, respectively. (b) Increased infiltration of CD4+ and CD8+ T cells into the tumors injected with HVJ-E solution. (c) Dose-dependent induction of interleukin-6 (IL-6), but not tumor necrosis factor α (TNF-α) or IL-12, secretion from splenocyte-derived dendritic cells following the treatment with HVJ-E. HVJ-E can lead DCs to secrete an equivalent amount of IL-6 as live HVJ.

regional lymph nodes 24 h after the administration of HVJ-E to immunostain the samples for IL-6, the DC-mediated production of IL-6 was found to be significantly increased in both types of CD11c-positive cells. Subsequently, CD4-positive and CD25-positive Tregs, as well as CD4-positive and CD25-negative effector T cells, were separated from the regional lymph nodes of a tumor-bearing mouse into which HVJ-E had been administered, in order to mix the effector T cells that were stimulated with the DCs collected from the spleen, with Tregs in various ratios, and the proliferation was examined in the mixed culture. The results showed that there was a decrease in the proliferation of effector cells associated with an increase in Tregs, and that this was suppressed by the administration of HVJ-E. Furthermore, this suppressive action was cancelled by adding anti-IL-6 antibodies to the mixed culture. On the basis of these results, it was assumed that HVJ-E functioned to avoid the suppression of the T-cell proliferation by Tregs due to the increased secretion of IL-6 from DCs, resulting in the strengthening and maintenance of the antitumor action of CD4- and CD8-positive T cells.

Clinical use of HVJ-E toward the treatment of melanoma

Pre-clinical studies. In the first reported pre-clinical study, mouse melanoma cell lines, B16/BL6, were subcutaneously transplanted

onto the backs of mice of the same strain (B16/BL6), and after a total of three injections of HVJ-E beginning on the fourth day, the weight changes in the mice were examined to check for the growth of tumor/metastatic lesions and the systemic safety. With respect to the examination of the tumor size, the transplanted cell lines in the group administered phosphate-buffered saline (PBS) started to form palpable tumors from approximately the eighth day, thus increasing in a logarithmic manner. On the other hand, there were dose-dependent growth suppression effects for 100 mNAU (neuraminidase activity unit), 300 mNAU and 1000 mNAU in the group receiving HVJ-E treatments (Figure 3a). The suppression of tumor proliferation was almost the same for 1000 mNAU and 2000 mNAU, so we elected to administer 1000 mNAU as the maximum dose (Figure 3b). Furthermore, when the survival of each group was examined, it was found that while all the mice that received transplants in the control (no treatment) group had died by the 40th day, a significant improvement in the survival rate was shown in the group receiving HVJ-E, with survival even at the 40th day in the group receiving 1000 mNAU, with a dose-dependent effect again being observed (Figure 3c).

Although transitory hemolysis was expected in HVJ-E-treated animals because it can agglutinate red blood cells due to its membrane structure, no serious side effects were found even in the mice undergoing administration of the maximum dose of

Figure 3. The antitumor effects of hemagglutinating virus of Japan envelope (HVJ-E) in implanted melanoma tissue. (a) The tumor growth was significantly decreased in a dose-dependent manner following the treatment with HVJ-E. (b) One thousand and 2000 mNAU of HVJ-E resulted in equivalent tumor growth suppression. (c) The survival rate was significantly improved in mice treated with HVJ-E compared with control. (d) No significant body weight loss was observed in the mice treated with HVJ-E. ** and *** indicate $P < 0.01$ and $P < 0.001$, respectively. (e) The significant tumor growth suppression (left side) and improved percent survival (right side) in mice bearing Mewo human melanoma cells.

2000 mNAU, and almost no changes in weight were found (Figure 3d). The B16/BL6 mouse melanoma cell line is known to induce spontaneous lung metastasis when intradermally transplanted into C57BL/6 mice.[27] Subsequently, the size of the lung metastasis in these individuals and the ratio of the mice in which metastasis appeared were examined on the 26th day after the tumor cell transplant. It was found that, while some form of metastasis was found in all 10 mice in the group treated with PBS, the rates and the sizes of metastatic lesions decreased in an HVJ-E dose-dependent manner. On the basis of this preliminary experiment, it was proven that HVJ-E also has a suppressive action on the proliferation of malignant melanoma, as well as a suppressive effect on natural distant metastasis in vivo. It has been considered that the human leukocyte antigen expression was reduced or absent in B16 melanoma cell lines,[28] and it is believed that natural killer (NK) cells may possibly be involved more than CTLs regarding this effect,[23] although the IL-18 produced by NK cells contradictorily participates in the PD-1-dependent tumor progression during cancer development.[29]

Following these findings, an experiment was implemented using human malignant melanoma (Mewo) cells. The Mewo cells were transplanted onto the backs of immunodeficient severe combined immunodeficiency mice, and intratumoral administration of HVJ-E was carried out every other day from the sixth day

with 1000 Hemagglutination Unit (equivalent to 200 mNAU) or 5000 Hemagglutination Unit (1000 mNAU) for a total of six times, to examine the tumor growth and survival rates. It was observed that the HVJ-E administration at 5000 Hemagglutination Unit significantly suppressed the tumor growth and extended the survival of the mice (Figure 3e). On the basis of these observations, it was concluded that non-T cell immunity was involved, in addition to the cell-mediated immunity focusing on T cells, in the antitumor effects of inactivated HVJ-E against malignant melanomas.

To investigate one of the potential mechanisms of action, we conducted a microarray analysis on Renca (mouse renal cancer) tumors that had been removed from severe combined immunodeficiency mice treated with HVJ-E, and found that CXCL10 was activated, together with type I IFN, showing that this chemokine was largely secreted from CD11c$^+$ DCs. Furthermore, it was confirmed through our experiments that CXCR3 was expressed on DX5$^+$ NK cells. Detailed examinations are underway regarding whether the antitumor effect, in which NK cells played the major role, can also be found against malignant melanoma, as expected.[23]

Following these promising preclinical studies of the antitumor effects of HVJ-E in vitro and in vivo, we have been engaged in the production of GMP grade HVJ-E with the intention of using it for

Table 1. The inclusion and exclusion criteria of our phase I/II trial using the HVJ-E preparation

Inclusion criteria
(1) The patient has provided a written informed consent before any study-related procedure
(2) The patient is at least over 20 years and $\leqslant 90$ years old
(3) The patient has a diagnosis of malignant tumor as confirmed by histopathology or cytology
(4) The patient has a diagnosis of malignant melanoma progressive melanoma in American Joint Committee on Cancer staging stage IIIC or stage IV
(5) The patient has one or more administrable lesion of HVJ-E solution on the skin, subcutis or lymph node ($<25\,cm^2$ in size measured by forceps calipers, CT or MRI review)
(6) The patient has a life expectancy for at least 12 weeks or more.
(7) The patient meets an Eastern Cooperative Oncology Group Performance Status Scale of 0 or 1
(8) The patient has measurable lesions (calipers, CT or MRI review)

Exclusion criteria
(1) The patient has multiple brain metastases
(2) The patient shows positive immune response by HVJ-E prick test at screening
(3) The patient has an uncontrolled serious complication such as active infection
(4) History of active autoimmune disease
(5) The patient is a pregnant or a lactating female
(6) The patient has a history of a transplantation of the allogeneic organ, the autologous organ or tissue
(7) The patient is inappropriate to be enrolled in this study judged by the doctors in charge

Abbreviations: CT, computed tomography; HVJ-E, hemagglutinating virus of Japan envelope; MRI, magnetic resonance imaging.

Figure 4. The decisions regarding target lesions and the intratumoral administration of the hemagglutinating virus of Japan envelope (HVJ-E) preparation into target #1.

clinical applications in humans. We established a purification method in 2008 using the bio-reactor production method and three-step column purification, together with the manufacturing of freeze-dried products. Furthermore, it has been confirmed in toxicity tests in mice, rats and monkeys that no serious organ injuries should occur even if the agent is administered in an amount ~ 18 times 10 000 mNAU (167 mNAU/kg) per dose, when the human body weight is assumed to be 60 kg.

Antibodies to HVJ-E are expected to appear and are expected to increase with the subsequent doses of HVJ-E based on the pre-clinical experiments in mice. However, the induced antibodies in mice did not inversely influence the antitumor immunity and tumor cell apoptosis *in vivo* (data not shown). This may be because HVJ-E is able to fuse to adjacent tumor cells and DCs within 3–5 s, and the subsequent antitumor immunity is dependent on HVJ-E-fused DCs and immunocompetent cells,

rather than on HVJ-E itself.[30] In addition, the HVJ envelope vector appears to be much less immunogenic than naïve HVJ, which strongly induces CTLs against virus-infected cells.[30] It is considered to be a major advantage that the antibodies to HVJ-E did not work as neutralizing antibodies, in contrast to most antibody drugs targeting specific molecules.

On the basis of these pre-clinical experiments and results, we prepared a protocol for a clinical study to test the safety and the tolerability of HVJ-E in stage IIIC or IV melanoma patients diagnosed according to the American Joint Committee on Cancer staging. After the protocol was approved by the Medical Ethics Committee at Osaka University in January 2009, we started the clinical study.

Purpose of this clinical study. This clinical study is a phase I/IIa clinical study, the main purpose of which is to confirm the safety

and the tolerability of HVJ-E preparations, and the secondary purpose of which is to measure the antitumor effects, in compliance with the inducibility of tumor immunity/RECIST version 1.1.[31]

Inclusion of subject cases. The detailed information about the study subjects is shown in Table 1. The target patients are those with progressive malignant melanomas, in stage IIIC or stage IV according to the American Joint Committee on Cancer classification, in whom no relapsing/resistance against standard therapy/ standard therapy has been noted, or those who refused standard therapy. The subjects were restricted to those cases between the ages of 20 and 90, who were able to provide informed consent describing their intention to participate in the clinical study. Furthermore, to implement the intratumoral administration of HVJ-E, patients must have skin, subcutaneous or lymph-node lesions with more than one administrable location of $<25\,cm^2$ (measured by vernier calipers, computed tomography, or magnetic resonance imaging) as an essential condition. The details of the selection/ exclusion criteria are shown in Table 1. With respect to the administration schedule, based on the preclinical safety and efficacy tests, one course is set to have a 4-week rest period after intratumoral administration of the HVJ-E preparation three times a week for 2 weeks, for a total of six injections (Figures 4a–d), and the above purposes will be assessed when two courses are completed. Patients shall be, in principle, hospitalized for 2 weeks while under administration and for the subsequent 2 weeks, to fully observe the general condition of the patients. Decisions regarding the applicability of study entries, final decisions on the effects, or decisions on cancellations due to adverse events, and so on shall be made by the members of the Effect and Safety Assessment Committee which is set outside the hospital.

Study duration and expected number of cases. The duration of the planned study is 30 months after receiving approval in July 2009, and the duration of entry will be 24 months. The expected number of cases is six cases: three cases for the lower dose of HVJ-E and three cases for higher dose of HVJ-E, with a maximum of 12 cases, using a standard design for a gradual increase in the cohort dosage.

General description of the HVJ-E preparation and schedule of the clinical study. Regarding the administration of the HVJ-E preparation, first, 1 ml of distilled water for injection will be added into a vial containing freeze-dried HVJ-E, the raw material, to make a liquid solution (suspension). Then, the suspension will be filtered with a 0.45-micrometer pore size filter. The HVJ-E preparation produced in the hospital in this manner is a white liquid solution (suspension) containing HVJ-E from 8000 mNAU to 10 000 mNAU per 1 ml. In the event that a lower dose is administered, HVJ-E diluted by 3.3-fold will be prepared with saline and used. The HVJ-E preparation will be intratumorally administered using an injectable syringe with an attached 27 Ga needle. With respect to the dosage, the lower dose group will receive 3000 mNAU and the higher dose group will receive 10 000 mNAU.

CONCLUSIONS AND FUTURE PERSPECTIVES

We have just started the world's first clinical study of the administration of inactivated HVJ virus into humans. From this standpoint, it was first planned as an experimental study to fully examine the safety and the tolerability of the HVJ-E preparation; subsequently, the protocol has been revised to assess the comprehensive antitumor immunity as a phase II trial that is expected to include patients with malignant melanomas, through collaboration with other laboratories. On the basis of the results of the initial clinical study introduced here, we are considering developing another clinical study later, in which specific molecules, such as IL-12, that are strong drivers toward the Th1

axis, will be enclosed in HVJ-E. On the basis of the results of this phase I trial, a sequential phase II trial is planned to evaluate the biphasic effect of HVJ-E in terms of the direct and indirect killing of tumors more extensively. On the other hand, recent advances in discoveries of the signaling cascades contributing to tumor development and paradoxical immunosuppression in melanoma have led to the development of immunomodulatory antibody drugs targeting CTLA-4 and PD-1 in T cells.[15,16] The protocol of the phase II study would be composed of a shortened interval of HVJ-E cessation and an increase in the dose to enhance its antitumor action. If the phase II trial is successful, we will then consider complementary immune-augmentation effects that might be obtained with the combined use of HVJ-E and the new immunomodulatory drugs. Therefore, when the phase I and II clinical trials using HVJ-E alone are finished in the near future, the combination can be administered as part of a phase III trial which includes >100 melanoma patients enrolled worldwide. Further clinical trials for patients with other malignancies, such as prostate cancer and glioblastoma, which showed high sensitivity to HVJ-E, can also be planned. These extended clinical uses are expected to provide a breakthrough for novel antitumor immunotherapy.

ABBREVIATIONS

CTL, cytotoxic T lymphocyte; CTLA-4, cytotoxic T-lymphocyte antigen 4; HVJ-E, hemagglutinating virus of Japan envelope; PD-1, programmed cell death-1; Treg, regulatory T cell

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

1 Lens MB, Eisen TG. Systemic chemotherapy in the treatment of malignant melanoma. *Expert Opin Pharmacother* 2003; **4**: 2205–2211.
2 Li Y, McClay EF. Systemic chemotherapy for the treatment of metastatic melanoma. *Semin Oncol* 2002; **29**: 413–426.
3 Ridolfi R, Petrini M, Fiammenghi L, Stefanelli M, Ridolfi L, Ballardini M *et al.* Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients. *J Transl Med* 2006; **4**: 36.
4 Wei Y, Sticca RP, Holmes LM, Burgin KE, Li J, Williamson J *et al.* Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. *Int J Oncol* 2006; **28**: 585–593.
5 Goto S, Kaneko T, Miyamoto Y, Eriguchi M, Kato A, Akeyama T *et al.* Combined immunocell therapy using activated lymphocytes and monocyte-derived dendritic cells for malignant melanoma. *Anticancer Res* 2005; **25**: 3741–3746.
6 Homma S, Kikuchi T, Ishiji N, Ochiai K, Takeyama H, Saotome H *et al.* Cancer immunotherapy by fusions of dendritic and tumor cells and rh-IL-12. *Eur J Clin Invest* 2005; **35**: 279–286.
7 Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM *et al.* Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. *J Natl Cancer Inst* 1998; **90**: 1894–1900.
8 Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL, Sherry RM *et al.* Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. *Clin Cancer Res* 2003; **9**: 2973–2980.
9 Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know. *Nat Rev Clin Oncol* 2011; **8**: 577–585.
10 Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U *et al.* Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. *J Clin Oncol* 2008; **26**: 5233–5239.
11 Hodi FS, O'day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB *et al.* Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010; **368**: 711–723.

12 Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. *Oncoimmunology* 2012; **1**: 1223–1225.

13 Kaneda Y, Saeki Y, Morishita R. Gene therapy using HVJ-liposomes: the best of both worlds? *Mol Med Today* 1999; **5**: 298–303.

14 Kaneda Y. A non-replicating oncolytic vector as a novel therapeutic tool against cancer. *BMB Rep* 2010; **43**: 773–780.

15 Kaneda Y. Virosome: a novel vector to enable multi-modal strategies for cancer therapy. *Adv Drug Deliv Rev* 2012; **64**: 730–738.

16 Kurooka M, Kaneda Y. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. *Cancer Res* 2007; **67**: 227–236.

17 Okada Y. Sendai virus-induced cell fusion. *Methods Enzymol* 1993; **221**: 18–41.

18 Kaneda Y. Applications of hemagglutinating virus of Japan in therapeutic delivery systems. *Expert Opin Drug Deliv* 2008; **5**: 221–233.

19 Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature* 1975; **256**: 495–497.

20 Jami J, Grandchamp S. Karyological properties of human-mouse somatic hybrids. *Proc Natl Acad Sci USA* 1971; **68**: 3097–3101.

21 Kaneda Y, Yamamoto S, Nakajima T. Development of HVJ envelope vector and its application to gene therapy. *Adv Genet* 2005; **53**: 307–332.

22 Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N et al. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. *Mol Ther* 2002; **6**: 219–226.

23 Fujiwara A, Kurooka M, Miki T, Kaneda Y. Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. *Cancer Immunol Immunother* 2008; **57**: 73–84.

24 Powrie F, Maloy KJ. Regulating the regulators. *Science* 2003; **299**: 1030–1031.

25 Fehervari Z, Sakaguchi S. Control of $Foxp3^+CD25^+CD4^+$ regulatory cell activation and function by dendritic cells. *Int Immunol* 2004; **16**: 1769–1780.

26 Wan S, Xia C, Morel L. IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4 + CD25 + T cell regulatory functions. *J Immunol* 2007; **178**: 271–279.

27 Overwijk WW, Restifo NP. B16 as a mouse model for human melanoma. *Curr Protoc Immunol* 2001; Chapter 20: Unit 20.1.

28 Ruiter DJ, Bergman W, Welvaart K, Scheffer E, van Vloten WA, Russo C et al. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. *Cancer Res* 1984; **44**: 3930–3935.

29 Terme M, Ullrich E, Aymeric L, Meinhardt K, Coudert J, Desbois M et al. Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. *Cancer Res* 2012; **72**: 2757–2767.

30 Kaneda Y, Yamamoto S, Nakajima T. Development of HVJ envelope vector and its application to gene therapy. *Adv Genet* 2005; **53**: 303–332.

31 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009; **45**: 228–247.

164

Immunological functions of the neuropilins and plexins as receptors for semaphorins

Atsushi Kumanogoh[1,2,3] and Hitoshi Kikutani[4,5]

Abstract | Semaphorins were originally identified as axon-guidance molecules that function during neuronal development. However, cumulative evidence indicates that semaphorins also participate in immune responses, both physiological and pathological, and they are now considered to be potential diagnostic and/or therapeutic targets for a range of diseases. The primary receptors for semaphorins are neuropilins and plexins, which have cell type-specific patterns of expression and are involved in multiple signalling responses. In this Review, we focus on the roles of neuropilin 1 (NRP1) and plexins in the regulation of the immune system, and we summarize recent advances in our understanding of their pathological implications.

[1]Division of
Immunopathology,
World Premier International
Immunology Frontier
Research Center, Osaka
University.
[2]Department of Respiratory
Medicine, Allergy and
Rheumatic Diseases,
Graduate School of Medicine,
Osaka University.
[3]Japan Science and
Technology, Core Research
for Evolutional Science and
Technology, Osaka
University, 2–2 Ymada-oka,
Suita, Osaka 565-0871,
Japan.
[4]Division of Molecular
Immunology, World Premier
International Immunology
Frontier Research Center,
Osaka University.
[5]Department of Molecular
Immunology, Research
Institute for Microbial
Diseases, Osaka University,
3–1 Ymada-oka, Suita,
Osaka 565-0871, Japan.
e-mails: kumanogo@imed3.
med.osaka-u.ac.jp;
kikutani@ragtime.biken.
osaka-u.ac.jp

Semaphorins were originally identified as axonal growth cone-collapsing proteins that are required to direct neuronal axons to their appropriate targets[1]. Since the 1990s, when their biological functions were first reported, more than 20 members of the semaphorin family have been found in vertebrates[2]. Two groups of proteins, the neuropilins (NRP1 and NRP2) and plexins (plexins A1, A2, A3, A4, B1, B2, B3, C1 and D1), have been identified as the main semaphorin receptors[3-5]. Secreted semaphorins (known as class 3 semaphorins) generally require NRPs as obligate co-receptors to interact with plexins, whereas most membrane-associated semaphorins (known as classes 4, 5, 6 and 7 semaphorins) directly bind to plexins (BOX 1; FIG. 1).

Recent findings have elucidated distinctive mechanistic aspects of these semaphorin receptors; for example, NRP1 is a regulatory T (T$_{Reg}$) cell marker[6-9], and there is crosstalk between plexin-mediated signalling and other signalling pathways, such as WNT- and insulin-like growth factor 1 (IGF1)-mediated signalling pathways[10,11]. In addition, the accumulated evidence has established that semaphorins and their receptors are involved in many processes beyond axon guidance, including cardiovascular development and growth[12,13], tumour progression, metastasis and suppression[14-16], osteoclastogenesis[10,11,17], homeostasis of the retina[18] and immune cell regulation[19-25]. Semaphorins and their receptors have crucial roles in various phases of physiological and pathological immune responses; these proteins constitute a family of immunoregulatory molecules that we refer to as immune semaphorins[26]. From a clinical point of view,

semaphorins and their receptors have been implicated in various human diseases, including tumorigenesis[5], tumour metastasis[27], neurodegenerative diseases[28] and immune disorders[29].

In light of these recent advances, semaphorins, as well as their receptors and their related signalling molecules, are considered to be potential diagnostic and therapeutic targets for various human diseases, including autoimmunity and allergy. In addition, recent protein structural studies have clearly determined the molecular basis for their ligand–receptor interactions, which provides powerful information to use to develop semaphorin-targeted therapies. In this Review, we discuss our rapidly increasing knowledge of the roles of semaphorin receptors in mice and, where possible, in humans (TABLE 1) to better understand their physiological and pathological implications.

Neuropilin 1

NRP1 and NRP2 are highly conserved transmembrane proteins that were originally identified as neuronal adhesion molecules that function during neuronal development[30]. NRPs were subsequently identified as neuronal receptors for secreted class 3 semaphorins such as semaphorin 3A (SEMA3A)[31,32]. As NRPs have short cytoplasmic domains (~40 amino acid residues in length) (FIG. 2), their signals are generally mediated through interacting co-receptors such as plexins[33,34]; for example, after binding to class 3 semaphorins, NRPs then associate with class A plexins[33,34]. NRPs also function as co-receptors for several other receptor systems that are involved in

Box 1 | Semaphorins and their receptors

The semaphorin family comprises a large number of phylogenetically conserved proteins that are structurally characterized by the Sema domain in their extracellular regions. The Sema domain has a seven-blade β-propeller structure containing sites for dimerization and binding to semaphorin receptors. On the basis of their carboxy-terminal structural features, semaphorins have been subdivided into eight classes. Members of class 3 are secreted, whereas the other vertebrate semaphorins are membrane associated (classes 4, 5 and 6 are transmembrane proteins, whereas class 7 proteins are membrane bound) and can be cleaved from the cell surface in certain conditions[3,5]. Of note, classes 1 and 2 are encoded by invertebrates. Class 8 semaphorins are virally encoded.

Generally, membrane-bound semaphorins (class 4–7) directly bind to plexins. By contrast, secreted semaphorins (class 3) require neuropilins (NRP1 and NRP2) as direct binding co-receptors to enable binding to plexins. However, a growing body of evidence has shown that semaphorin–receptor interactions are more complex than this; for example, semaphorin 3E (SEMA3E) — a secreted semaphorin — directly binds to plexin D1, without NRPs. In both the nervous and immune systems, SEMA7A associates with integrins in addition to plexin C1. In the immune system specifically, SEMA4A and SEMA4D use T cell immunoglobulin and mucin domain-containing protein 2 (TIM2) and CD72, respectively, as a receptor in addition to members of the plexin B family.

In vertebrates, the plexin family consists of nine members, which are canonical semaphorin receptors involved in mediating cytoplasmic signals. In the nervous system, plexin-mediated signals regulate the activities of GTPases and of cytoplasmic or receptor-type protein kinases, as well as regulating integrin-mediated attachment. Plexins can associate with different co-receptors to confer pleiotropic functions on semaphorins; for example, in heart morphogenesis, plexin A1 forms heterodimers with the tyrosine kinase receptors off-track (OTK) and vascular endothelial growth factor receptor 2 (VEGFR2), whereas during osteoclastogenesis, plexin A1 forms receptor complexes with triggering receptor expressed on myeloid cells 2 (TREM2)– DNAX activation protein 12 (DAP12) and NRP1. Plexin B1 associates with the receptor tyrosine kinases MET and ERBB2 to induce the invasive growth of epithelial cells. Thus, semaphorins can trigger multiple signalling cascades to carry out their diverse biological activities.

Axonal growth-cone collapsing proteins
Molecules that induce the loss of motile activity and the cessation of advance of growth cones (the growing tips of axons). Such an axonal guidance process is important to establish connections between pathways in the developing nervous system.

VEGF₁₆₅
The most active and abundant splice variant of vascular endothelial growth factor (VEGF). It functions as a growth factor in angiogenesis, vasculogenesis and endothelial cell growth.

Experimental autoimmune encephalomyelitis
(EAE). A widely used animal model for studies of multiple sclerosis, which is an inflammatory demyelinating disease of the central nervous system (CNS). It is induced by stimulating an immune response directed against CNS antigens.

---

development, immunity and cancer[35]; for example, NRP1 is a receptor for vascular endothelial growth factor (VEGF) family members (including the splice variant VEGF₁₆₅), which are expressed by endothelial cells and tumour cells[36], as well as for transforming growth factor-β1 (TGFβ1)[37]. The extracellular domains of NRPs have been shown to have adhesive properties; therefore, careful and critical evaluation of the interactions between NRP1 and other receptors and ligands will be required to definitively determine the roles of NRP1. In addition, it has been reported that the short cytoplasmic domain of NRP1 has a role in integrin functions and VEGF signalling[38–40]. The immunological analysis of NRP2, which has a similar structure to NRP1, is still in its infancy. In this Review, we describe what is known about the role of NRP1 in the immune system.

Expression in the immune system. In recent years, it has become clear that NRP1 has a role in the immune response. During the search for human dendritic cell (DC) markers, NRP1 was identified as blood DC antigen 4 (BDCA4; also known as CLEC4C and CD304), which is expressed by plasmacytoid DCs (pDCs)[41]. pDCs express Toll-like receptors (TLRs) and thereby recognize viral nucleic acids, which results in the production of high levels of type I interferons (IFNs)[42]. Therefore, the functional role of NRP1 in pDCs has been investigated in the context of viral infection. Incubation of pDCs with an NRP1-specific antibody blocks the induction of IFNα production by viral infection or nucleic acids[43]. However, the mechanisms that contribute to this phenotype remain unclear.

In the human thymus, NRP1 is expressed on the cell surface of developing T cells; thus, NRP1 expression can be detected in both the cortex and the medulla of the thymus[44]. NRP1 expression has also been observed in thymic epithelial cells (TECs) and DCs, which indicates that it might be involved in thymocyte development. In addition, *in vitro* co-culture experiments indicate that NRP1 forms homophilic interactions at the cell–cell contacts between T cells and DCs, which suggests that it contributes to the primary immune response in the lymph nodes[45]. However, it remains unclear how and to what extent such homophilic interactions are physiologically relevant to immune responses.

Inhibitory functions: a regulatory T cell marker? The functions of NRP1 in the immune system have been linked to immune inhibition. NRP1 is a specific marker for mouse CD4⁺CD25⁺ T$_{Reg}$ cells, although it is poorly expressed by human T cells. Microarray profiling showed that *Nrp1* is a forkhead box P3 (FOXP3)-inducible gene, as are *CD25* (also known as *IL2RA*), glucocorticoid-induced TNF receptor-related protein (*GITR*; also known as *TNFRSF18*) and cytotoxic T lymphocyte antigen 4 (*CTLA4*)[6,46]. NRP1 expressed by T$_{Reg}$ cells might help to increase the contact time between T$_{Reg}$ cells and DCs through its homophilic interaction with DC-expressed NRP1, which might thereby stabilize the interaction between these cells and prevent naive T cells from interacting with DCs[46]. Therefore, NRP1 seems to contribute to the negative regulation of immune responses by increasing T$_{Reg}$ cell activities. A growing body of evidence supports the idea that NRP1 is functionally relevant in T$_{Reg}$ cell-mediated immune suppression. First, the lack of NRP1 on CD4⁺ T cells results in increased severity of experimental autoimmune encephalomyelitis (EAE). In addition, T cells from mice with a conditional knockout of *Nrp1* show preferential commitment to the T helper 17 (T$_H$17) cell lineage and decreased T$_{Reg}$ cell functions[47]. Second, NRP1⁺ T$_{Reg}$ cells accumulate in the draining lymph nodes of metastatic tumours, which suggests that NRP1 has a

166

Figure 1 | **The structure of and interactions between semaphorins and their receptors.** Semaphorins are characterized by an extracellular amino-terminal Sema domain followed by one or more cysteine-rich PSI (plexin, semaphorin and integrin) domains. Plexins, which are the most common receptors of semaphorins, consist of an N-terminal Sema domain, followed by a combination of PSI domains and IPTs (immunoglobulin domains shared by plexins and transcription factors) in their extracellular regions. Crystallization studies have shown that semaphorins and plexins interact through their Sema domains. Secreted-type class 3 semaphorins typically require the co-receptor neuropilin 1 (NRP1) to interact with the class A plexin receptor complex. However, semaphorin 3E (SEMA3E) can bind to plexin D1 in a NRP-independent manner (not shown). Membrane-associated class 4 semaphorins bind to class B and class D plexin receptors. In lymphocytes, SEMA4A also binds T cell immunoglobulin and mucin domain-containing protein 2 (TIM2) and SEMA4D binds CD72. Class 6 semaphorins bind class A plexin receptors and do not require NRPs; for example, SEMA6A binds to plexin A4. SEMA6D carries out different biological activities through plexin A1 depending on its co-receptor (that is, off-track or vascular endothelial growth factor receptor 2 (VEGFR2)). SEMA7A signals are mediated through β1 integrin receptors in both the nervous system and the immune system, and SEMA7A also binds to plexin C1. Plexin C1 is also known as the receptor of viral semaphorins, such as A39R (from poxvirus) and AHV-Sema (from alcelaphine herpesvirus type 1). GAP, GTPase-activating protein.

role in the suppression of antitumour immunity[48]. Third, CD4+ T cell-specific ablation of NRP1 expression results in delayed tumorigenesis in mouse transplanted-tumour models; these tumours contain activated intratumoral CD8+ T cells[7]. Finally, it has recently been reported that NRP1 is important to potentiate T_{Reg} cell functions and survival[49]. In addition, NRP1 has been shown to be crucial for the suppressive activities of T_{Reg} cells in experimental models of antitumour immunity and colitis. Collectively, these findings strongly indicate that NRP1 is involved in T_{Reg} cell-mediated immunosuppression in mice.

A recent report showed that NRP1 expression distinguishes thymus-derived T_{Reg} cells from peripherally derived T_{Reg} cells[8,9]. By comparing gene expression levels between thymus-derived and peripherally derived T_{Reg} cells using microarrays, NRP1 was found to be expressed at high levels by most thymus-derived T_{Reg} cells but not by mucosa-generated peripherally derived T_{Reg} cells. This indicates that distinct types of infiltrating T_{Reg} cells are involved in different inflammatory conditions[8]. In addition, using T cell receptor-transgenic mice that have defined self antigen specificity,

167

Table 1 | **The roles of semaphorins and their receptors in the immune system**

Semaphorins and their receptors	Expression in immune cells	Binding partners	Activities	Related diseases
NRP1	• T cells • T_{Reg} cells • Tumour cells • Endothelial cells	• Class 3 semaphorins • VEGF • Co-receptor for TGFβ, HGF, PDGF and their receptors • Heparin, integrins, fibronectin and SEMA4A	Inhibitory: T cell activation* and tumour angiogenesis*‡	• Cancer[7] • SLE[117]
Plexin A1	• DCs • Plasmacytoid DCs • Osteoclasts	Class 6 semaphorins	Stimulatory: DC activation*, production of type I interferons*‡ and differentiation of osteoclasts*	• EAE[17] • Osteopetrosis[17]
Plexin A4	• T cells • DCs • Macrophages	Class 6 semaphorins	Inhibitory: T cell activation*	• EAE[69] • Sepsis[70]
Plexin B1	• Microglia • Oligodendrocytes	Class 7 semaphorins	• Stimulatory: microglial activation* and injury of oligodendrocytes* • Inhibitory: differentiation of osteoblasts*	• EAE[79] • HAM[78] • Osteoporosis[10]
Plexin D1	CD4⁺CD8⁺ thymocytes	SEMA3E	Stimulatory: migration of thymocytes into the medulla[91]*	NA
TIM2	• Activated T cells • T_H2 cells	SEMA4A	Stimulatory: T cell activation*	EAE[22]
CD72	• B cells • DCs	SEMA4D	Stimulatory: B cell activation*‡ and DC activation*	SLE[118]
α1β1 integrin	• Monocytes • Macrophages	SEMA7A	Stimulatory: monocyte and macrophage activation*	• EAE[24] • Pulmonary fibrosis[88]
SEMA3A	• T cells • Tumour cells • Endothelial cells	Class A plexins	Stimulatory: differentiation of osteoblasts* Inhibitory: monocyte migration*‡, T cell activation*‡, tumour angiogenesis*‡ and osteoclast differentiation*	• Atopic dermatitis[102] • Allergic rhinitis[104] • Osteoporosis[11] • Rheumatoid arthritis[119] • Multiple sclerosis[120] • SLE[100,101] • Cardiac dysrhythmia[121] • Cancer[122]
SEMA3E	Thymus (especially in the medulla)	Plexin D1	Stimulatory: migration of thymocytes into the medulla[91]*	NA
SEMA4A	• DCs • Activated T cells • T_H1 cells	Class B plexins Plexin D1 TIM2	Stimulatory: T cell activation* and T_H1 cell differentiation*	• EAE or multiple sclerosis[22,96] • Atopic dermatitis[105] • Pigmentary retinopathy[18]
SEMA4B	• T cells • B cells	Not known	Inhibitory: basophil-mediated T_H2 cell skewing[123]*	NA
SEMA4D	• T cells • Activated B cells • DCs	Plexin B1 CD72	Stimulatory: B cell activation*‡, DC activation*‡, microglial activation* and injury of oligodendrocytes*	• EAE[79] • HAM[78] • Immunodeficiency syndrome[21] • Osteopetrosis[10]
SEMA6A	• DCs • Langerhans cells	Not known	Stimulatory: granuloma formation‡	• LC histiocytosis and dermatopathic lymphadenitis[124] • GPA[125]
SEMA6D	• T cells • B cells • NK cells	Plexin A1	Stimulatory: DC activation*	Osteopetrosis[17]
SEMA7A	Activated T cells	• Plexin C1 • α1β1 integrin	Stimulatory: monocyte and macrophage activation*‡	• Contact hypersensitivity[24] • EAE[24] • Pulmonary fibrosis[88]

DC, dendritic cell; EAE, experimental autoimmune encephalomyelitis; GPA, granulomatosis with polyangiitis; HAM, HTLV1-associated myelopathy; HGF, hepatocyte growth factor; LC, Langerhans cell; NA, not applicable; NK, natural killer; NRP1, neuropilin 1; PDGF, platelet-derived growth factor; SEMA, semaphorin; SLE, systemic lupus erythematosus; TIM2, T cell immunoglobulin and mucin domain-containing protein 2; TGFβ, transforming growth factor-β; T_H, T helper; T_{Reg}, regulatory T; VEGF, vascular endothelial growth factor. *The activity has been shown in mouse systems. ‡The activity has been shown in human systems.

168

REVIEWS

Figure 2 | **The structure and binding sites of neuropilins.** Neuropilins (NRPs) have two complement-binding homology domains (a1 and a2), two coagulation factor V and VII homology domains (b1 and b2) and a meprin domain (c) in their extracellular regions. Cumulative findings indicate that a and b domains are crucial for ligand binding, including binding to semaphorin 3A (SEMA3A) and vascular endothelial growth factor splice variant VEGF$_{165}$. Of note, several studies have shown that the b1 domain mediates the high-affinity binding of NRPs to the basic domain of class 3 semaphorins and to VEGFA[108–111], such that VEGFA and class 3 semaphorins can compete for their binding to the b1 domain of NRPs[111–114]. In addition, it has been suggested that the b1 domain of NRP1 binds with high affinity to the basic domain of SEMA3A, whereas the a1 domain of NRP1 helps the Sema domain of SEMA3A to coordinate with the Sema domain of class A plexins and probably to activate the signalling of class A plexins[114–116]. SEA represent the last amino acid residues (Ser, Glu and Ala) of the cytoplasmic domain, which provide binding to the PDZ (PSD95, DLGA and ZO1 homology) domain-containing protein GIPC1 (also known as synectin).

another study also showed that NRP1 is expressed at high levels in thymus-derived T$_{Reg}$ cells and that it can be used to distinguish between thymus-derived T$_{Reg}$ cells and peripherally derived T$_{Reg}$ cells. This indicates that there are functional differences between these cells[9]. Collectively, these data indicate that NRP1 is a marker that distinguishes thymus-derived from peripherally derived T$_{Reg}$ cells, at least in mice. However, further careful investigation will be required to determine whether NRP1 is a stable marker for thymus-derived T$_{Reg}$ cells, as well as whether these findings are applicable to human T$_{Reg}$ cells. In addition, it still remains unclear what the binding partner for NRP1 on T$_{Reg}$ cells might be.

As noted above, NRP1 functions as a co-receptor for multiple ligands in addition to semaphorins, such as VEGF and TGFβ1, which indicates that semaphorins might interact with or compete with other ligands, thereby altering the signalling outcome; for example, VEGF$_{165}$ promotes microvessel outgrowth, whereas SEMA3A suppresses this effect[50]. As a result of the adhesive properties of the NRP extracellular domains, a considerable number of molecules have been reported to be NRP1 ligands. Although NRP1 is thought to function as a 'hub' receptor for different ligands, such adhesive-binding characteristics can produce controversial and confusing results that require further investigation. Of note, it has recently been reported that SEMA4A binds to NRP1 and is relevant to NRP1-mediated T$_{Reg}$ cell functions and stability[49]. However, there are no apparent defects in the development and functions of FOXP3⁺ T$_{Reg}$ cells in SEMA4A-deficient mice in physiological conditions[51]. Therefore, regarding the ligands for NRP1 and the

mechanisms of NRP1-mediated functions, definitive comprehensive studies using gene-targeted mice and biochemical ligand-binding analysis will be necessary to determine the precise biological roles of NRP1 in T$_{Reg}$ cell-mediated immune functions[35].

Plexins

As NRPs have short cytoplasmic tails and are generally unable to generate signals by themselves, cytoplasmic signalling that is mediated by plexins is considered to be crucial to generate semaphorin-mediated biological functions. Plexins are divided into four classes in vertebrates: class A (plexins A1, A2, A3 and A4), class B (plexins B1, B2 and B3), class C (plexin C1) and class D (plexin D1)[3,5]. The members of the plexin family have highly conserved cytoplasmic domains that encode a GTPase-activating protein (GAP) for RAS-related protein (R-RAS), as well as a GTPase-binding domain and split GAP domains[3,52,53]. In addition, the cytoplasmic domains of plexins associate with other signalling molecules, such as RHO family GTPases, p21-activated kinase (PAK), p190 RHO GAP (also known as RHO GTPase-activating protein 35)[54], PDZ (PSD95, DLGA and ZO1 homology)-RHOGEFs (RHO guanine nucleotide exchange factors)[55,56], flavoprotein monooxygenases (also known as MICALs)[57], the FERM domain-containing GEFs known as FARPs[58,59], RAS-related protein M-RAS[60] and RAP1 (REF. 61). Plexins are crucial for actomyosin contraction and microtubule destabilization, and plexin-mediated signalling has been implicated in the inhibition of integrin-mediated cellular adhesion and cytoskeletal remodelling[4,50,58] (FIG. 3). Furthermore, plexins use tissue- and cell lineage-specific co-receptors, including cytoplasmic and receptor-type protein kinases, which thereby enables semaphorins to carry out diverse functions[17,62,63] (BOX 1). In this section, we focus on several members of the plexin family for which immunological functions have been identified.

Plexin A1 in DC-mediated immune responses. Plexin A1 is a receptor for both class 3 (secreted) and class 6 (transmembrane) semaphorins. SEMA3A binds a receptor complex formed by class A plexins and NRP1 (REF. 33), whereas the class 6 semaphorins SEMA6C and SEMA6D directly bind to class A plexins[25,63]. In the immune system, it has been shown that plexin A1 expression is induced by the MHC class II transactivator (CIITA)[64]. Indeed, plexin A1 is expressed at high levels in mature DCs, but at low or undetectable levels in other immune cells such as macrophages, B cells and T cells. Studies using RNA interference and plexin A1-deficient mice have determined the functional importance of plexin A1 in DC-mediated immune responses. Using short hairpin RNA to target plexin A1 expression, it was shown that plexin A1 is involved in the activation of T cells by DCs[64]. Consistent with those findings, we showed that plexin A1-deficient mice have impaired generation of antigen-specific T cells[17,25]. These studies strongly indicate that plexin A1 is required for DC-mediated T cell responses.

169

Figure 3 | **Effects of semaphorins on integrin function. a** | Suppression of integrin functions by semaphorin 3A (SEMA3A) is shown. SEMA3A binding to the neuropilin 1 (NRP1)–plexin A1 receptor complex triggers the dissociation of FERM domain-containing GEF 2 (FARP2) from NRP1, which has two major roles. First, the RAC guanine nucleotide exchange factor (GEF) activity of FARP2 is activated, which is essential for subsequent recruitment of RND1 to plexin A1 and for the activation of the RAS-related protein (R-RAS) GTPase-activating protein (GAP) activity of plexin A1, which leads to the downregulation of R-RAS activity. Second, released FARP2 binds to PIPKIγ661 (phosphatidylinositol phosphate kinase type Iγ 661) and inhibits its PIPKIγ kinase activity, which leads to the inhibition of integrin functions and focal adhesion. **b** | SEMA7A positively and negatively regulates immune responses through different integrin receptors. SEMA7A that is expressed on activated T cells stimulates peripheral macrophages through α1β1 integrin, which leads to the production of pro-inflammatory cytokines such as interleukin-6 (IL-6), tumour necrosis factor (TNF) and IL-1β. In addition, SEMA7A that is expressed on intestinal epithelial cells induces IL-10 production by intestinal macrophages through αvβ1 integrin. CX₃CR1, CX₃C-chemokine receptor 1; TCR, T cell receptor.

the cell body, which enables cells to pass through narrow gaps. In addition, adoptive-transfer experiments showed that SEMA3A that is secreted by lymphatic endothelial cells is involved in the regulation of DC trafficking from peripheral tissues to draining lymph nodes. It is plausible that semaphorins (probably class 3 secreted semaphorins) that are produced by vascular endothelial cells[65] are also involved in enabling other immune cells to pass through blood vessel walls by regulating their adhesion activities and contractility in a plexin-dependent manner.

Plexin A1 in osteoimmunology. Osteoimmunology is an interdisciplinary research field, in which the interplay between the skeletal and immune systems is studied at the molecular level. A breakthrough in our understanding of plexin A1-mediated signalling was recently made in the field of osteoimmunology (FIG. 4). Disruption of the gene encoding plexin A1 results in abnormalities in both immune responses and bone homeostasis. Regarding the bone phenotype, plexin A1-deficient mice develop osteopetrosis because of decreased bone resorption that is caused by defective development of osteoclasts; SEMA6D is suggested to function as a ligand for plexin A1 in osteoclast differentiation[17,59]. Indeed, both SEMA6D and plexin A1 are expressed by osteoclasts and recombinant SEMA6D can enhance *in vitro* osteoclastogenesis. Plexin A1 forms a functional receptor complex with triggering receptor expressed on myeloid cells 2 (TREM2) and the adaptor molecule DNAX-activation protein 12 (DAP12; also known as TYROBP) on osteoclasts[17]. However, as both SEMA3A and SEMA6D can use plexin A1 as a receptor component, how do their different modes of action regulate bone homeostasis?

Nrp1-knock-in mice in which the activities of SEMA3A are impaired — through the mutation of the NRP1 a1 domain that is responsible for mediating the interaction between the Sema domains of SEMA3A and class A plexins (FIG. 2) — had osteoporosis that was identical to that of SEMA3A-deficient mice[11]. This study showed that, in the absence of receptor activator of NF-κB ligand (RANKL; also known as TNFSF11), SEMA3A that is produced by osteoblasts binds to NRP1–plexin A1 on osteoclast precursor cells and hinders the interaction between plexin A1 and the TREM2-DAP12 complex, thereby suppressing SEMA6D-induced osteoclastogenesis[11]. By contrast, in the presence of RANKL, the expression of NRP1 is downregulated and SEMA6D binds to the plexin A1-TREM2-DAP12 receptor complex to enhance osteoclastogenesis. The authors also found that SEMA3A repels osteoclast precursor cells to prevent excessive bone disruption, which suggests that the end result of SEMA3A function is decreased osteoclast differentiation and decreased osteopetrosis. In addition to the osteoclast phenotype, deficiency of either SEMA3A or NRP1 results in a decreased number of osteoblasts, decreased expression of osteoblast genes including *Runx2* and alkaline phosphatase liver/bone/kidney isozyme (*Alpl*) and decreased bone formation, which indicates that SEMA3A positively regulates osteoblast differentiation. SEMA3A promotes the activation

Regarding the mechanisms of plexin A1 function, our imaging study showed that plexin A1 is involved in sensing SEMA3A during DC migration, particularly for the steps that are involved in transmigration across the lymphatics. During DC migration, plexin A1 is localized at the rear of migrating DCs; in this region, SEMA3A produced by lymphatic endothelial cells induces myosin light-chain phosphorylation to squeeze

Osteopetrosis
A rare inherited disorder characterized by abnormally dense and brittle bones. It is caused by the failure of osteoclasts to resorb bone.

170

Figure 4 | **Plexin A1- and plexin B1-mediated signalling in bone homeostasis. a** | Semaphorin 6D (SEMA6D)–plexin A1-mediated intracellular signalling in osteoclasts during receptor activator of NF-κB ligand (RANKL) stimulation is shown. In the presence of SEMA6D expressed by osteoclasts, plexin A1 forms a receptor complex with triggering receptor expressed on myeloid cells 2 (TREM2) and DNAX-activation protein 12 (DAP12), which mediates osteoclast differentiation through calcium signalling downstream of phospholipase Cγ (PLCγ) activation. In the presence of RANKL, neuropilin 1 (NRP1) is downregulated in osteoclasts, so SEMA3A does not have an effect on plexin A1 signalling. **b** | The function of the SEMA3A–plexin A1–NRP1 complex in osteoblast differentiation is shown. Soluble SEMA3A, which is released from osteoblasts, binds to plexin A1 and NRP1 on osteoblasts. This complex signals through FERM domain-containing GEF 2 (FARP2) to activate the small G protein RAC1, which subsequently promotes WNT3A-induced accumulation of β-catenin in the nucleus. Thus, this signalling pathway induces the differentiation of osteoblasts. **c** | The crosstalk between plexin B1 and insulin-like growth factor 1 (IGF1) signalling is shown. The binding of SEMA4D to plexin B1 contributes to RHOA activation by RHO guanine nucleotide exchange factors (GEFs) in the intracellular region of plexin B1. RHOA activates the downstream kinase RHO-associated protein kinase 1 (ROCK1), which leads to the suppression of IGF1-mediated signalling through phosphorylation of insulin receptor substrate 1 (IRS1); this therefore leads to the inhibition of osteoblast differentiation. APC, adenomatous polyposis coli; AXIN1, axis inhibitor 1; Dvl, Disheveled; GSK3β, glycogen synthase kinase 3β; IGF1R, IGF1 receptor; LRP, low-density lipoprotein receptor-related protein; TCF, T cell-specific transcription factor.

Osteoclasts
Multinucleated cells of haematopoietic origin that degrade the bone matrix. They have a crucial role in both physiological and pathological bone resorption.

Osteoporosis
A common disease that is characterized by low bone mass, microarchitectural disruption and skeletal fragility, which results in an increased risk of fracture. An oversupply of osteoclasts relative to the need for remodelling or an undersupply of osteoblasts relative to the need for cavity repair are important pathophysiological changes in osteoporosis.

of the small G protein RAC1 through FARP2, which enhances WNT3A-induced nuclear accumulation of β-catenin. β-catenin signalling pathways are essential for the differentiation of mesenchymal precursor cells into osteoblasts or adipocytes in bone homeostasis[11] (FIG. 4b). Therefore, these findings indicate not only that there is crosstalk between semaphorin signalling and WNT signalling but also that targeting semaphorins might be a novel molecular basis for the development of anti-osteoclastogenic agents.

Plexin A4: negative and positive roles in the immune system. In the nervous system, plexin A4 functions as a receptor for SEMA3A and SEMA6A[66]. Plexin A4 has a major role in transducing SEMA3A signalling not only in neurons but also in endothelial cells[67]. However, the roles of plexin A4 in the immune system seem to differ from those of plexin A1. Plexin A4 is expressed by T cells, DCs and macrophages[68], and it has negative

regulatory roles in various immune responses[69]. We previously reported that plexin A4-deficient mice have enhanced T cell priming and exacerbated disease in a mouse model of EAE[69]. By contrast, plexin A4 seems to have a positive function in TLR-mediated signalling, as plexin A4 defects in innate immune cells result in decreased inflammatory cytokine production in response to TLR stimuli[70]. It has been suggested that plexin A4 is required for activation of the small GTPase RAC1 and that it thereby modulates JUN N-terminal kinase (JNK) and nuclear factor-κB (NF-κB) activation in macrophages in response to TLR stimuli. Accordingly, plexin A4-deficient mice have attenuated TLR-mediated inflammation, including septic shock[70]. In this situation, SEMA3A — which is upregulated in lymphoid lineage cells such as B cells, T cells, DCs and NK cells following TLR stimulation — functions as a ligand. These findings suggest plexin A4 as a potential therapeutic target for the treatment of sepsis and the related cytokine storm.

171

Plexin B1 and B2 as receptors for class 4 semaphorins.
Class B plexins are most similar to the scatter-factor receptors, which are a family of transmembrane receptors that lead to invasive growth and that are implicated in cancer[71]. Among the class B plexins, the functions of plexin B1 and plexin B2 have been delineated in the context of the class 4 semaphorin SEMA4D[34,72,73]. Plexin B1 has high affinity for SEMA4D[34], which also uses CD72 as an additional receptor in lymphocytes[20,21].

In the immune system, plexin B1 is expressed by activated T cells and immature bone marrow-derived DCs (but not by mature DCs or monocytes)[74], as well as by bone marrow stromal cells, follicular DCs[75], microglia and lung DCs[68,76]. On the basis of its expression pattern, several studies have indicated that through its interactions with SEMA4D, plexin B1 has the following functional roles in the immune system: soluble SEMA4D inhibits the migration of immature DCs and this inhibition can be blocked by plexin B1-specific antibodies[74]; ligation of plexin B1 on B cells by SEMA4D induces increased B cell proliferation and lifespan[75]; plexin B1 expression on renal glomeruli facilitates the recruitment of SEMA4D-expressing macrophages[77]; and SEMA4D activates microglia through plexin B1 and transfer of myelin oligodendrocyte glycoprotein (MOG)-specific T cells into plexin B1-deficient mice results in attenuated development of EAE[78,79].

The signalling pathways downstream of plexin B1 that are triggered by SEMA4D have been delineated in terms of axonal growth-cone collapse — a process in which small GTPases have been implicated as mediators of the biological functions of semaphorins[56,80,81]; for example, plexin B1 activates RHOA through the interaction of the carboxy-terminal PDZ-binding domains of plexin B1 with PDZ-RHOGEF and leukaemia-associated RHOGEF (LARG; also known as RHOGEF12). In addition, SEMA4D induces the recruitment of active RACto the cytoplasmic region of plexin B1, which leads to the inhibition of PAK, which is a downstream effector of RAC[82].

The signalling mechanisms of plexin B1 have also been identified in the field of osteoimmunology (FIG. 4c). Osteoclasts and osteoblasts express SEMA4D and plexin B1, respectively; these interactions inhibit bone formation[10]. During a search for axon-guidance molecules that function in bone remodelling, it was found that the expression of SEMA4D in osteoclasts is upregulated during RANKL-induced osteoclastogenesis, and that deficiency of either SEMA4D or plexin B1 results in high bone mass phenotypes. The PDZ domain of plexin B1 contributes to RHOA activation through RHOGEFs in osteoblasts[10], and dominant-negative RHOA-expressing mice have a high bone mass phenotype similar to that of SEMA4D-deficient and plexin B1-deficient mice. The RHOA–ROCK1 (RHO-associated protein kinase 1) pathway inhibits the phosphorylation of insulin receptor substrate 1 (IRS1), which is involved in IGF1-induced signalling. IGF1 is an important factor for osteoblastogenesis, so its suppression by plexin B1-mediated signals (through the RHOA–ROCK1 pathway) decreases bone formation by osteoblasts. Indeed, SEMA4D suppresses

phosphorylation of IRS1 at a tyrosine residue that is essential for AKT and mitogen-activated protein kinase (MAPK) activation, which shows that there is crosstalk between plexin and IGF1 signalling (FIG. 4c).

The functional importance of SEMA4D–plexin B2 interactions has also recently been determined[83,84]. Plexin B2 is involved in the epithelial repair process through its interaction with SEMA4D[84]. THY1+ dendritic epidermal T cells (DETCs) — a type of γδ T cell — express SEMA4D whereas plexin B2 is expressed in keratinocytes; plexin B2 has effects on DETCs and SEMA4D-mediated γδ T cell morphology, which indicates that cytoplasmic signals through SEMA4D can be triggered by plexin B2 as a ligand. SEMA4D-deficient mice have defective DETC responses to keratinocyte damage, which results in delayed healing of cutaneous wounds. In addition, negative regulatory roles of plexin B2 in IL-12 or IL-23 p40 subunit production by DCs have been identified[83].

Plexin C1 and integrins. Both plexin C1 and β1 integrins are receptors for the membrane-associated glycosyl-phosphatidylinositol (GPI)-anchored semaphorin SEMA7A[24,34,85,86]. Plexin C1 was initially identified as a receptor for SEMA7A and virally encoded semaphorins[34,87]. The viral semaphorins A39R (from poxvirus) and AHV-Sema (from alcelaphine herpesvirus type 1) bind to virus-encoded semaphorin protein receptor (VESPR) (also known as plexin C1 and CD232) and induce the production of pro-inflammatory cytokines, thereby modulating the pathogenesis of these viral infections; these effects can be abrogated with a plexin C1-blocking antibody[87]. Similarly, we have shown that recombinant soluble SEMA7A protein has effects on macrophages that include the upregulation of expression of intercellular adhesion molecule 1 (ICAM1) and the induction of expression of pro-inflammatory cytokines such as tumour necrosis factor (TNF) and IL-6 (REF. 24); this finding substantiates the role of SEMA7A in inflammatory responses.

However, although plexin C1 was initially identified as a receptor for SEMA7A, the biological activities of SEMA7A have been delineated in the context of its interactions with integrins. SEMA7A contains an Arg-Gly-Asp sequence, which is a well-conserved integrin-binding motif. In the immune system, we have shown that SEMA7A that is expressed on activated T cells is involved in inducing the production of pro-inflammatory cytokines by macrophages through α1β1 integrin (also known as VLA1)[24]. Consistent with these findings, SEMA7A-deficient mice are defective in cell-mediated immune responses, including hapten-induced contact hypersensitivity[24] and TGFβ1-induced lung fibrosis[88], in which β1 integrin functions as a receptor component. These findings indicate the importance of the interactions between SEMA7A and α1β1 integrin in T cell-mediated macrophage activation. Moreover, we recently showed that SEMA7A that is expressed on intestinal epithelial cells negatively regulates activation of intestinal macrophages through αvβ1 integrin and that this has an important role in intestinal homeostasis[86]. Thus, SEMA7A has both positive and negative regulatory functions by associating with different types of β1 integrin (FIG. 3).

Scatter-factor receptors
A family of transmembrane receptors, of which MET and RON tyrosine kinases are members. MET is the receptor for hepatocyte growth factor and RON is the receptor for macrophage-stimulating protein.

172

REVIEWS

Plexin D1 in SEMA3E-mediated cellular navigation.
Plexin D1 was initially identified because of its key role in development of the vasculature[13,89]; plexin D1 deficiency results in congenital heart defects as a result of improper vessel patterning[89]. SEMA3E and SEMA4A were identified as ligands for plexin D1 (REFS 89,90).

In the immune system, the SEMA3E–plexin D1 axis has a role in thymocyte development[91]. The expression of plexin D1 on thymocytes decreases during development of CD4+CD8+ double-positive thymocytes to CD4+ or CD8+ single-positive thymocytes, and SEMA3E is preferentially expressed in the medulla of the thymus. Chemotaxis assays carried out *in vitro* have shown that SEMA3E binds to CD4+CD8+CD69+ cells and inhibits their CC-chemokine receptor 9 (CCR9)-mediated migration. Consistent with this finding, the thymus in plexin D1-deficient embryos is disorganized compared with the thymus from wild-type control embryos. In addition, when fetal liver cells derived from plexin D1-deficient embryos were transferred to SEMA3E-deficient mice, the boundary between double-positive and single-positive thymocytes at the corticomedullary junction was disrupted[91]. These findings indicate that plexin D1 is involved in the development of thymocytes and of thymic architecture.

Several additional roles for plexin D1 in the immune system have been determined. Plexin D1-mediated signals are relevant to germinal centre formation and long-term B cell immune responses[92]. Plexin D1 is expressed by DCs and its absence results in increased production of the IL-12 and IL-23 p40 subunit[83]. Plexin D1 and its ligand SEMA4A are expressed on macrophages, and macrophage migration towards SEMA4A is abrogated in the presence of plexin D1-blocking antibodies[93]. However, the plexin D1-mediated signalling mechanisms that control these immune responses remain unclear and require further study.

As described here, cumulative findings indicate that semaphorin receptors have diverse roles in several phases of immune responses, from the initiation of a response to the terminal inflammatory immune reactions. Of note, immune cells circulate and interact with other systems such as the nervous, vascular, epithelial and skeletal systems. Therefore, semaphorin receptor-mediated biological activities could enhance our understanding of the 'bigger picture' of physiological and pathological immune responses *in vivo*.

Use as diagnostic and therapeutic targets
In the past few years, it has become clear that semaphorins and their receptors are crucially involved in the pathogenesis of various human diseases and that they are therefore potential diagnostic or therapeutic targets[92,94] (TABLE 1). In the context of the involvement of these proteins in the pathogenesis of immunological disorders, many studies have investigated the relationship between semaphorins and multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus (SLE), allergic diseases and graft-versus-host disease (GVHD). In this section, we focus on the roles of semaphorins in these diseases.

Multiple sclerosis. Multiple sclerosis is a demyelinating autoimmune disease of the central nervous system and a leading cause of lasting neurological disabilities in young adults; EAE is commonly used as an animal model of this disease and has provided evidence of a pathological role for various semaphorins. SEMA3A that is produced in the lymphatics functions as a ligand for the plexin A1–NRP1 receptor complex expressed by DCs, which regulates DC migration from the peripheral tissues to the lymph nodes for antigen presentation to T cells. The lack of SEMA3A–NRP1–plexin A1 interactions results in attenuated development of EAE because of impaired T cell responses[25]. Recent evidence has highlighted the pathological importance of immune cell migration as a therapeutic target in multiple sclerosis; for example, fingolimod (also known as FTY720) and an α4β1 integrin-specific antibody suppress the relapsing forms of multiple sclerosis by inhibiting cellular migration. Therefore, SEMA3A–NRP1–plexin A1 interactions are potential therapeutic targets for multiple sclerosis.

SEMA4D is highly expressed by T cells and is crucially involved in T cell activation, which requires DC maturation[20,95]. Indeed, SEMA4D-deficient mice show attenuated EAE because of impaired T cell priming[21,95]. It seems that SEMA4D is crucially involved in the pathogenesis of EAE, particularly in the initial phases of pathogenic T cell activation that are mediated by interactions between T cells and DCs.

In addition to its pathological roles in the periphery in terms of T cell activation, we have shown that SEMA4D also contributes to neuro-inflammation in the central nervous system, where SEMA4D that is expressed on the cell surface of T cells induces the activation of microglial cells through plexin B1 as well as inducing the death of immature neural cells. Consistent with these findings, SEMA4D-blocking antibodies inhibited neuro-inflammation, which thereby attenuated the development of EAE[79]. Collectively, these findings indicate that blocking SEMA4D not only inhibits the generation of encephalitogenic T cells but also suppresses the inflammatory neural damage that occurs after clinical onset of EAE. Clinical trials using SEMA4D-blocking antibodies to treat multiple sclerosis have been initiated in the United States (ClinicalTrials.gov, number: NCT01764737).

SEMA4A is highly expressed in DCs and has been shown to have a crucial role in T$_H$ cell differentiation[22,23]. SEMA4A is also involved in the pathogenesis of EAE and multiple sclerosis. Indeed, blocking antibodies that are specific for SEMA4A attenuate EAE, and SEMA4A-deficient mice are resistant to EAE[22,23] as a result of their decreased generation of MOG peptide-specific CD4+ T cells.

We recently reported that the serum levels of soluble SEMA4A are increased in patients with multiple sclerosis[96]. Specifically, in these patients, SEMA4A expression is increased on the cell surface of DCs and SEMA4A is shed from these cells. Patients with high SEMA4A levels have T$_H$17 cell skewing as well as severe disabilities and unresponsiveness to IFNβ therapy. Taken together, these results not only indicate that SEMA4A is involved

Fingolimod
An oral sphingosine-1-phosphate receptor modulator that sequesters lymphocytes in the lymph nodes, which prevents them from contributing to an immune reaction. It is approved for the treatment of multiple sclerosis, in which it decreases the rate of relapses in relapsing remitting multiple sclerosis.

173

Table 2 | Immunological phenotypes of knockout mice of semaphorins and their receptors

Semaphorins and their receptors	Phenotypes of knockout mice	Refs
SEMA3A	• Impaired T cell priming	25
	• Impaired migration of DCs to the lymph nodes	25
SEMA3E	• Impaired antigen-specific activation of T cells	92
	• Impaired development of thymocytes in the thymus	91
SEMA4A	• Impaired T_H1 cell responses induced by *Propionibacterium acnes*	23
	• Enhanced T_H2 cell responses induced by *Nippostrongylus brasiliensis*	23
	• Impaired antigen presentation by DCs	23
SEMA4B	Enhanced basophil-mediated responses	123
SEMA4D	• Impaired activation of DCs	95
	• Impaired activation of B cells	20
	• Impaired migration of monocytes induced by chemokines	126
	• Impaired secretion of iNOS from microglial cells	79
	• Impaired platelet responses to vascular injury	127
SEMA6D	No defects in T cell priming	25
SEMA7A	• Impaired activation of macrophages	24
	• Resistance to EAE	24
	• Hypersensitivity to EAE	128
	• Resistance to experimental contact dermatitis	24
	• Enhanced responses to DSS-induced colitis	86
	• Resistance to lung fibrosis	88
Plexin A1	Impaired migration of DCs to the lymph nodes	25
Plexin A4	• Enhanced T cell proliferation after TCR stimulation	69
	• Enhanced responses of EAE	69
	• Resistance to septic shock	70
Plexin B1	Impaired SEMA4D-mediated microglial activation	79
Plexin B2	Impaired SEMA4D-mediated microglial activation	79
Plexin C1	Impaired SEMA7A-mediated monocyte activation	129
Plexin D1	Impaired development of thymocytes in the thymus	91

DC, dendritic cell; DSS, dextran sodium sulphate; EAE, experimental autoimmune encephalomyelitis; iNOS, inducible nitric oxide synthase; SEMA, semaphorin; T_H, T helper; TCR, T cell receptor.

in the pathogenesis of multiple sclerosis by promoting T_H17 cell skewing but also suggest that SEMA4A could be a diagnostic or a prognostic marker of multiple sclerosis.

SEMA7A is expressed by activated T cells and interacts with α1β1 integrin that is expressed by macrophages to promote the production of pro-inflammatory cytokines. SEMA7A-deficient mice are resistant to EAE and SEMA7A has been pathologically implicated in the effector phase of EAE through its interaction with α1β1 integrin[24].

Rheumatoid arthritis and SLE. Rheumatoid arthritis is a chronic inflammatory disorder that typically affects small- and medium-sized peripheral joints, in which the articular cartilage and the surrounding bones are destroyed by proliferative synovitis. The synovial lesion in rheumatoid arthritis is formed by inflammatory cell invasion, proliferation of the lining cells and increased angiogenesis, a process in which expression of the $VEGF_{165}$ splice variant and its receptor NRP1 have been implicated[97]. Furthermore, a recent report showed that treatment with an anti-NRP1 peptide could suppress the development of experimental arthritis in mice[98], which indicates that similar peptides could be worth testing for the treatment of chronic arthritis.

CD4[+] T cells that are derived from patients with rheumatoid arthritis have defective SEMA3A expression. SEMA3A enhances the suppressive ability of CD4[+]NRP1[+] T cells, which leads to IL-10 production and regulatory activities[99]. Furthermore, several reports have suggested that SEMA3A is important in the pathogenesis of SLE[100,101]. Serum SEMA3A levels, which are decreased in patients with SLE, inversely correlate with the severity of SLE, including the presence of renal damage and of serum cardiolipin-specific antibodies[100]. These findings indicate that SEMA3A is a potential therapeutic agent for SLE.

Allergic diseases. The pathological implications of semaphorins have also been reported for allergic diseases. The therapeutic effects of SEMA3A on atopic dermatitis have been shown using mouse models in the context of neuro-immune crosstalk. Atopic dermatitis is a chronically relapsing itch or inflammatory skin condition that markedly reduces the quality of life. Itching sensations are conducted by afferent C fibres, which are unmyelinated nerve fibres that originate from neurons of the dorsal root ganglia. In normal conditions, the free nerve endings of C fibres are located at the boundary between the epidermis and the dermis. By contrast, in patients with atopic dermatitis, C fibres in the epidermis increase

Atopic dermatitis
A chronic inflammatory, relapsing and itchy skin disorder. Impaired epidermal barrier functions and allergic responses have important roles in the pathogenesis of atopic dermatitis.

174

REVIEWS

NC/Nga mice
A well-described animal model for atopic dermatitis. In conventional housing conditions, these mice develop skin lesions that are clinically and histologically similar to human atopic dermatitis.

and sprout, probably in response to the nerve growth factor (NGF) that is produced by keratinocytes or fibroblasts in response to scratching, which results in hypersensitivity and more itching[94]. Intracutaneous injection of SEMA3A protein into the skin lesions of NC/Nga mice, which are an animal model of atopic dermatitis, attenuated several symptoms, such as scratching behaviour, erosion and oedema[102]. The validity of this therapeutic strategy is supported by the finding that patients with atopic dermatitis have lower levels of SEMA3A in the epidermis compared with control patients. In addition, it has been reported that the expression of SEMA3A is lower in psoriatic skin than in skin from healthy control patients, whereas the expression of NGF is higher[103]. Given these findings, it is reasonable to conclude that decreased SEMA3A expression is involved in the development of itching and skin inflammation in both atopic dermatitis and psoriasis. On a related note, decreased SEMA3A expression in the nasal mucosa might contribute to nasal hypersensitivity during allergic rhinitis[104], and intranasal administration of recombinant SEMA3A decreases sneezing and nasal rubbing symptoms in mouse rhinitis models[104]. Therefore, it seems that SEMA3A is required for the homeostasis of the C fibres that conduct itching sensations by balancing the effects of NGF.

SEMA4A has been implicated in the regulation of T_H cell differentiation[23], and increased levels of SEMA4A may be involved in the pathogenesis of autoimmunity[96]. By contrast, SEMA4A insufficiency results in allergic diseases, including atopic dermatitis and airway hypersensitivity[105,106]. In a model of ovalbumin-specific experimental asthma, SEMA4A-deficient mice had enhanced airway hyper-reactivity with increased pulmonary eosinophil infiltration, which was associated with increased levels of T_H2-type cytokines and IgE in bronchoalveolar lavage fluid. Consistent with these observations, recombinant SEMA4A protein suppresses T_H2-type cytokine production and the severity of airway hyper-reactivity. Thus, it is plausible that SEMA4A has therapeutic potential for allergic diseases.

GVHD. Acute GVHD is a major complication in allogeneic bone marrow transplantation, in which donor T cells respond to alloantigens on recipient DCs. In mouse allogeneic bone marrow transplantation, it has been shown that mice transplanted with SEMA4D-deficient T cells

have decreased mortality and GVHD-mediated target organ damage[107], which shows the potential therapeutic application of blocking SEMA4D in tissue and/or organ transplantation.

As described here, new evidence is emerging that semaphorins and their receptors are crucial for the pathogenesis of several diseases, particularly for diseases in which several biological systems, such as the immune, nervous and vascular systems, are involved. Thus, blocking signalling that is mediated by semaphorins might have beneficial effects not only for attenuating immune responses but also for protecting tissues or promoting tissue repair.

Conclusions

Semaphorins form a family of immunoregulatory molecules. In conjunction with their receptors — mainly neuropilins and plexins — semaphorins mediate multiple biological activities. A lack of semaphorin signalling results in several immune disorders — including autoimmune and allergic diseases — but excess semaphorin signalling can also induce disease. Thus, semaphorins and their receptors have crucial roles in maintaining immunological homeostasis. An increased understanding of the mechanisms by which semaphorins and their receptors regulate the immune system should aid in the development of therapeutic targets for several human diseases.

However, several issues still remain to be clarified. First, although NRPs and plexins have been found to mediate cell motility and morphology through their role as semaphorin receptors in the nervous system, it is unknown how and to what extent they also regulate immune cell trafficking *in vivo*. Second, we need to clarify the molecular basis for the multiple biological activities of semaphorins in different tissues and cells in both physiological and pathological conditions. Third, the details of ligand–receptor interactions remain unclear because of the controversial and confusing nature of findings regarding the adhesive properties of the extracellular domains of NRPs and plexins. Fourth, for the potential clinical application of semaphorins and their receptors, side effects outside of the immune system — for example, in the central nervous and vascular systems — must be considered. To address these issues, careful and definitive evaluation using gene-targeted mice or binding analyses will be crucial (TABLE 2), not only to fully elucidate the functions of these molecules but also to identify potential diagnostic and therapeutic targets for immune disorders.

1. Kolodkin, A. L., Matthes, D. J. & Goodman, C. S. The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules. *Cell* **75**, 1389–1399 (1993).
2. Semaphorin Nomenclature Committee. Unified nomenclature for the semaphorins/collapsins. *Cell* **97**, 551–552 (1999).
3. Pasterkamp, R. J. Getting neural circuits into shape with semaphorins. *Nature Rev. Neurosci.* **13**, 605–618 (2012).
4. Takamatsu, H. & Kumanogoh, A. Diverse roles for semaphorin-plexin signaling in the immune system. *Trends Immunol.* **33**, 127–135 (2012).
5. Tamagnone, L. Emerging role of semaphorins as major regulatory signals and potential therapeutic targets in cancer. *Cancer Cell* **22**, 145–152 (2012).

6. Bruder, D. *et al.* Neuropilin-1: a surface marker of regulatory T cells. *Eur. J. Immunol.* **34**, 623–630 (2004).
7. Hansen, W. *et al.* Neuropilin 1 deficiency on CD4⁺Foxp3⁺ regulatory T cells impairs mouse melanoma growth. *J. Exp. Med.* **209**, 2001–2016 (2012).
8. Weiss, J. M. *et al.* Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3⁺ T reg cells. *J. Exp. Med.* **209**, 1723–1742 (2012).
9. Yadav, M. *et al.* Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets *in vivo. J. Exp. Med.* **209**, 1713–1722 (2012).
    References 8 and 9 show that NRP1 is a marker of thymus-derived but not of peripherally derived T_Reg cells and that it is involved in T_Reg cell functions.

10. Negishi-Koga, T. *et al.* Suppression of bone formation by osteoclastic expression of semaphorin 4D. *Nature Med.* **17**, 1473–1480 (2011).
    This study shows that SEMA4D inhibits bone formation by inhibiting IGF1-induced signals.
11. Hayashi, M. *et al.* Osteoprotection by semaphorin 3A. *Nature* **485**, 69–74 (2012).
    This study identifies the osteoprotective effects of SEMA3A and its crosstalk with WNT signals.
12. Toyofuku, T. *et al.* Guidance of myocardial patterning in cardiac development by Sema6D reverse signalling. *Nature Cell Biol.* **6**, 1204–1211 (2004).
13. Gu, C. *et al.* Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins. *Science* **307**, 265–268 (2005).

175

14. Casazza, A. *et al*. Sema3E–Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. *J. Clin. Invest.* **120**, 2684–2698 (2010). **This study shows that SEMA3E–plexin D1 interactions are relevant to the malignancies and the metastatic activities of human cancers.**

15. Maione, F. *et al*. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. *J. Clin. Invest.* **122**, 1832–1848 (2012).

16. Maione, F. *et al*. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. *J. Clin. Invest.* **119**, 3356–3372 (2009).

17. Takegahara, N. *et al*. Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis. *Nature Cell Biol.* **8**, 615–622 (2006). **This is the first definitive study to show that plexin A1 is indispensable in both immune and skeletal systems.**

18. Toyofuku, T. *et al*. Endosomal sorting by semaphorin 4A in retinal pigment epithelium supports photoreceptor survival. *Genes Dev.* **26**, 816–829 (2012).

19. Bougeret, C. *et al*. Increased surface expression of a newly identified 150-kDa dimer early after human T lymphocyte activation. *J. Immunol.* **148**, 318–323 (1992).

20. Kumanogoh, A. *et al*. Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling. *Immunity* **13**, 621–631 (2000). **This is the first report to show that semaphorins have crucial roles in the immune system.**

21. Shi, W. *et al*. The class IV semaphorin CD100 plays nonredundant roles in the immune system: defective B and T cell activation in CD100-deficient mice. *Immunity* **13**, 633–642 (2000). **This is the first knockout study in mice to show that semaphorins are crucial for immune responses.**

22. Kumanogoh, A. *et al*. Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2. *Nature* **419**, 629–633 (2002).

23. Kumanogoh, A. *et al*. Nonredundant roles of Sema4A in the immune system: defective T cell priming and Th1/Th2 regulation in Sema4A-deficient mice. *Immunity* **22**, 305–316 (2005).

24. Suzuki, K. *et al*. Semaphorin 7A initiates T-cell-mediated inflammatory responses through α1β1 integrin. *Nature* **446**, 680–684 (2007).

25. Takamatsu, H. *et al*. Semaphorins guide the entry of dendritic cells into the lymphatics by activating myosin II. *Nature Immunol.* **11**, 594–600 (2010). **This is the first definitive study using imaging analysis to show that plexins are involved in immune cell migration.**

26. Suzuki, K., Kumanogoh, A. & Kikutani, H. Semaphorins and their receptors in immune cell interactions. *Nature Immunol.* **9**, 17–23 (2008).

27. Capparuccia, L. & Tamagnone, L. Semaphorin signaling in cancer cells and in cells of the tumor microenvironment — two sides of a coin. *J. Cell Sci.* **122**, 1723–1736 (2009).

28. Nojima, S. *et al*. A point mutation in Semaphorin 4A associates with defective endosomal sorting and causes retinal degeneration. *Nature Commun.* **4**, 1406 (2013).

29. Okuno, T., Nakatsuji, Y. & Kumanogoh, A. The role of immune semaphorins in multiple sclerosis. *FEBS Lett.* **585**, 3829–3835 (2011).

30. Takagi, S. *et al*. The A5 antigen, a candidate for the neuronal recognition molecule, has homologies to complement components and coagulation factors. *Neuron* **7**, 295–307 (1991).

31. He, Z. & Tessier-Lavigne, M. Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. *Cell* **90**, 739–751 (1997).

32. Kolodkin, A. L. *et al*. Neuropilin is a semaphorin III receptor. *Cell* **90**, 753–762 (1997).

33. Takahashi, T. *et al*. Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors. *Cell* **99**, 59–69 (1999).

34. Tamagnone, L. *et al*. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. *Cell* **99**, 71–80 (1999). **This study establishes the concept of semaphorin–plexin interactions.**

35. Prud'homme, G. J. & Glinka, Y. Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity. *Oncotarget* **3**, 921–939 (2012).

36. Soker, S., Takashima, S., Miao, H. Q., Neufeld, G. & Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. *Cell* **92**, 735–745 (1998). **This study identifies that NRP1 is a receptor for VEGF.**

37. Glinka, Y. & Prud'homme, G. J. Neuropilin-1 is a receptor for transforming growth factor β1, activates its latent form, and promotes regulatory T cell activity. *J. Leukoc. Biol.* **84**, 302–310 (2008).

38. Robinson, S. D. *et al*. αvβ3 integrin limits the contribution of neuropilin-1 to vascular endothelial growth factor-induced angiogenesis. *J. Biol. Chem.* **284**, 33966–33981 (2009).

39. Valdembri, D. *et al*. Neuropilin-1/GIPC1 signaling regulates α5β1 integrin traffic and function in endothelial cells. *PLoS Biol.* **7**, e25 (2009).

40. Lanahan, A. *et al*. The neuropilin 1 cytoplasmic domain is required for VEGF-A-dependent arteriogenesis. *Dev. Cell* **25**, 156–168 (2013).

41. Dzionek, A. *et al*. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. *J. Immunol.* **165**, 6037–6046 (2000).

42. Reizis, B., Bunin, A., Ghosh, H. S., Lewis, K. L. & Sisirak, V. Plasmacytoid dendritic cells: recent progress and open questions. *Annu. Rev. Immunol.* **29**, 163–183 (2011).

43. Grage-Griebenow, E. *et al*. Anti-BDCA-4 (neuropilin-1) antibody can suppress virus-induced IFN-α production of plasmacytoid dendritic cells. *Immunol. Cell Biol.* **85**, 383–390 (2007).

44. Lepelletier, Y. *et al*. Control of human thymocyte migration by neuropilin-1/semaphorin-3A-mediated interactions. *Proc. Natl Acad. Sci. USA* **104**, 5545–5550 (2007).

45. Tordjman, R. *et al*. A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. *Nature Immunol.* **3**, 477–482 (2002).

46. Sarris, M., Andersen, K. G., Randow, F., Mayr, L. & Betz, A. G. Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. *Immunity* **28**, 402–413 (2008).

47. Solomon, B. D., Mueller, C., Chae, W. J., Alabanza, L. M. & Bynoe, M. S. Neuropilin-1 attenuates autoreactivity in experimental autoimmune encephalomyelitis. *Proc. Natl Acad. Sci. USA* **108**, 2040–2045 (2011).

48. Battaglia, A. *et al*. Neuropilin-1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer. *Immunology* **123**, 129–138 (2008).

49. Delgoffe, G. M. *et al*. Stability and function of regulatory T cells is maintained by a neuropilin-1–semaphorin-4a axis. *Nature* **501**, 252–256 (2013).

50. Serini, G. *et al*. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. *Nature* **424**, 391–397 (2003).

51. Makino, N. *et al*. Involvement of Sema4A in the progression of experimental autoimmune myocarditis. *FEBS Lett.* **582**, 3935–3940 (2008).

52. Oinuma, I., Ishikawa, Y., Katoh, H. & Negishi, M. The Semaphorin 4D receptor Plexin-B1 is a GTPase activating protein for R-Ras. *Science* **305**, 862–865 (2004).

53. Tamagnone, L. & Mazzone, M. Semaphorin signals on the road of endothelial tip cells. *Dev. Cell* **21**, 189–190 (2011).

54. Barberis, D. *et al*. p190 Rho-GTPase activating protein associates with plexins and it is required for semaphorin signalling. *J. Cell Sci.* **118**, 4689–4700 (2005).

55. Perrot, V., Vazquez-Prado, J. & Gutkind, J. S. Plexin B regulates Rho through the guanine nucleotide exchange factors leukemia-associated Rho GEF (LARG) and PDZ-RhoGEF. *J. Biol. Chem.* **277**, 43115–43120 (2002).

56. Swiercz, J. M., Kuner, R., Behrens, J. & Offermanns, S. Plexin-B1 directly interacts with PDZ-RhoGEF/LARG to regulate RhoA and growth cone morphology. *Neuron* **35**, 51–63 (2002).

57. Terman, J. R., Mao, T., Pasterkamp, R. J., Yu, H. H. & Kolodkin, A. L. MICALs, a family of conserved flavoprotein oxidoreductases, function in plexin-mediated axonal repulsion. *Cell* **109**, 887–900 (2002).

58. Toyofuku, T. *et al*. FARP2 triggers signals for Sema3A-mediated axonal repulsion. *Nature Neurosci.* **8**, 1712–1719 (2005).

59. Takegahara, N. *et al*. Integral roles of a guanine nucleotide exchange factor, FARP2, in osteoclast podosome rearrangements. *FASEB J.* **24**, 4782–4792 (2010).

60. Saito, Y., Oinuma, I., Fujimoto, S. & Negishi, M. Plexin-B1 is a GTPase activating protein for M-Ras, remodelling dendrite morphology. *EMBO Rep.* **10**, 614–621 (2009).

61. Wang, Y. *et al*. Plexins are GTPase-activating proteins for Rap and are activated by induced dimerization. *Sci. Signal.* **5**, ra6 (2012).

62. Giordano, S. *et al*. The semaphorin 4D receptor controls invasive growth by coupling with Met. *Nature Cell Biol.* **4**, 720–724 (2002).

63. Toyofuku, T. *et al*. Dual roles of Sema6D in cardiac morphogenesis through region-specific association of its receptor, Plexin-A1, with off-track and vascular endothelial growth factor receptor type 2. *Genes Dev.* **18**, 435–447 (2004).

64. Wong, A. W. *et al*. CIITA-regulated plexin-A1 affects T-cell-dendritic cell interactions. *Nature Immunol.* **4**, 891–898 (2003).

65. Gu, C. & Giraudo, E. The role of semaphorins and their receptors in vascular development and cancer. *Exp. Cell Res.* **319**, 1306–1316 (2013).

66. Suto, F. *et al*. Interactions between plexin-A2, plexin-A4, and semaphorin 6A control lamina-restricted projection of hippocampal mossy fibers. *Neuron* **53**, 535–547 (2007).

67. Kigel, B., Rabinowicz, N., Varshavsky, A., Kessler, O. & Neufeld, G. Plexin-A4 promotes tumor progression and tumor angiogenesis by enhancement of VEGF and bFGF signaling. *Blood* **118**, 4285–4296 (2011).

68. Roney, K., Holl, E. & Ting, J. Immune plexins and semaphorins: old proteins, new immune functions. *Protein Cell* **4**, 17–26 (2013).

69. Yamamoto, M. *et al*. Plexin-A4 negatively regulates T lymphocyte responses. *Int. Immunol.* **20**, 413–420 (2008).

70. Wen, H., Lei, Y., Eun, S. Y. & Ting, J. P. Plexin-A4–semaphorin 3A signaling is required for Toll-like receptor- and sepsis-induced cytokine storm. *J. Exp. Med.* **207**, 2943–2957 (2010).

71. Tamagnone, L. & Comoglio, P. M. Signalling by semaphorin receptors: cell guidance and beyond. *Trends Cell Biol.* **10**, 377–383 (2000).

72. Deng, S. *et al*. Plexin-B2, but not Plexin-B1, critically modulates neuronal migration and patterning of the developing nervous system *in vivo*. *J. Neurosci.* **27**, 6333–6347 (2007).

73. Artigiani, S. *et al*. Functional regulation of semaphorin receptors by proprotein convertases. *J. Biol. Chem.* **278**, 10094–10101 (2003).

74. Chabbert-de Ponnat, I. *et al*. Soluble CD100 functions on human monocytes and immature dendritic cells require plexin C1 and plexin B1, respectively. *Int. Immunol.* **17**, 439–447 (2005).

75. Granziero, L. *et al*. CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5⁺ B lymphocytes. *Blood* **101**, 1962–1969 (2003).

76. Smith, E. P. *et al*. Expression of neuroimmune semaphorins 4A and 4D and their receptors in the lung is enhanced by allergen and vascular endothelial growth factor. *BMC Immunol.* **12**, 30 (2011).

77. Li, M. *et al*. Endogenous CD100 promotes glomerular injury and macrophage recruitment in experimental crescentic glomerulonephritis. *Immunology* **128**, 114–122 (2009).

78. Giraudon, P. *et al*. Semaphorin CD100 from activated T lymphocytes induces process extension collapse in oligodendrocytes and death of immature neural cells. *J. Immunol.* **172**, 1246–1255 (2004).

79. Okuno, T. *et al*. Roles of Sema4D–plexin-B1 interactions in the central nervous system for pathogenesis of experimental autoimmune encephalomyelitis. *J. Immunol.* **184**, 1499–1506 (2010).

80. Oinuma, I., Katoh, H., Harada, A. & Negishi, M. Direct interaction of Rnd1 with Plexin-B1 regulates PDZ-RhoGEF-mediated Rho activation by Plexin-B1 and induces cell contraction in COS-7 cells. *J. Biol. Chem.* **278**, 25671–25677 (2003).

81. Basile, J. R., Barac, A., Zhu, T., Guan, K. L. & Gutkind, J. S. Class IV semaphorins promote angiogenesis by stimulating Rho-initiated pathways through plexin-B. *Cancer Res.* **64**, 5212–5224 (2004).

82. Vikis, H. G., Li, W. & Guan, K. L. The plexin-B1/Rac interaction inhibits PAK activation and enhances Sema4D ligand binding. *Genes Dev.* **16**, 836–845 (2002).

REVIEWS

83. Holl, E. K. et al. Plexin-B2 and Plexin-D1 in dendritic cells: expression and IL-12/IL-23p40 production. *PLoS ONE* 7, e43333 (2012).

84. Witherden, D. A. et al. The CD100 receptor interacts with its plexin B2 ligand to regulate epidermal γδ T cell function. *Immunity* 37, 314–325 (2012).

85. Pasterkamp, R. J., Peschon, J. J., Spriggs, M. K. & Kolodkin, A. L. Semaphorin 7A promotes axon outgrowth through integrins and MAPKs. *Nature* 424, 398–405 (2003).

86. Kang, S. et al. Intestinal epithelial cell-derived semaphorin 7A negatively regulates development of colitis via αvβ1 integrin. *J. Immunol.* 188, 1108–1116 (2012).

87. Comeau, M. R. et al. A poxvirus-encoded semaphorin induces cytokine production from monocytes and binds to a novel cellular semaphorin receptor, VESPR. *Immunity* 8, 473–482 (1998).

88. Kang, H. R., Lee, C. G., Homer, R. J. & Elias, J. A. Semaphorin 7A plays a critical role in TGF-β1-induced pulmonary fibrosis. *J. Exp. Med.* 204, 1083–1093 (2007).

89. Gitler, A. D., Lu, M. M. & Epstein, J. A. PlexinD1 and semaphorin signaling are required in endothelial cells for cardiovascular development. *Dev. Cell* 7, 107–116 (2004).

90. Toyofuku, T. et al. Semaphorin-4A, an activator for T-cell-mediated immunity, suppresses angiogenesis via Plexin-D1. *EMBO J.* 26, 1373–1384 (2007).

91. Choi, Y. I. et al. PlexinD1 glycoprotein controls migration of positively selected thymocytes into the medulla. *Immunity* 29, 888–898 (2008).

92. Holl, E. K. et al. Plexin-D1 is a novel regulator of germinal centers and humoral immune responses. *J. Immunol.* 186, 5603–5611 (2011).

93. Meda, C. et al. Semaphorin 4A exerts a proangiogenic effect by enhancing vascular endothelial growth factor-A expression in macrophages. *J. Immunol.* 188, 4081–4092 (2012).

94. Goshima, Y., Sasaki, Y., Yamashita, N. & Nakamura, F. Class 3 semaphorins as a therapeutic target. *Expert Opin. Ther. Targets* 16, 933–944 (2012).

95. Kumanogoh, A. et al. Requirement for the lymphocyte semaphorin, CD100, in the induction of antigen-specific T cells and the maturation of dendritic cells. *J. Immunol.* 169, 1175–1181 (2002).

96. Nakatsuji, Y. et al. Elevation of Sema4A implicates Th cell skewing and the efficacy of IFN-β therapy in multiple sclerosis. *J. Immunol.* 188, 4858–4865 (2012).

97. Ikeda, M., Hosoda, Y., Hirose, S., Okada, Y. & Ikeda, E. Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis. *J. Pathol.* 191, 426–433 (2000).

98. Kong, J. S. et al. Anti-neuropilin-1 peptide inhibition of synoviocyte survival, angiogenesis, and experimental arthritis. *Arthritis Rheum.* 62, 179–190 (2010).

99. Catalano, A. The neuroimmune semaphorin-3A reduces inflammation and progression of experimental autoimmune arthritis. *J. Immunol.* 185, 6373–6383 (2010).

100. Vadasz, Z. et al. Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosus. *Arthritis Res. Ther.* 14, R146 (2012).

101. Vadasz, Z. & Toubi, E. Semaphorin 3A - a marker for disease activity and a potential putative disease-modifying treatment in systemic lupus erythematosus. *Lupus* 21, 1266–1270 (2012).

102. Yamaguchi, J. et al. Semaphorin3A alleviates skin lesions and scratching behavior in NC/Nga mice, an atopic dermatitis model. *J. Invest. Dermatol.* 128, 2842–2849 (2008).

103. Kou, K. et al. Decreased expression of semaphorin-3A, a neurite-collapsing factor, is associated with itch in psoriatic skin. *Acta Derm. Venereol* 92, 521–528 (2012).

104. Sawaki, H. et al. Intranasal administration of semaphorin-3A alleviates sneezing and nasal rubbing in a murine model of allergic rhinitis. *J. Pharmacol. Sci.* 117, 34–44 (2011).

105. Nkyimbeng-Takwi, E. H. et al. Neuroimmune semaphorin 4A downregulates the severity of allergic response. *Mucosal Immunol.* 5, 409–419 (2012).

106. Morihana, T. et al. An inhibitory role for Sema4A in antigen-specific allergic asthma. *J. Clin. Immunol.* 33, 200–209 (2013).

107. Duran-Struuck, R. et al. A novel role for the semaphorin Sema4D in the induction of allo-responses. *Biol. Blood Marrow Transplant.* 13, 1294–1303 (2007).

108. Adams, R. H., Lohrum, M., Klostermann, A., Betz, H. & Puschel, A. W. The chemorepulsive activity of secreted semaphorins is regulated by furin-dependent proteolytic processing. *EMBO J.* 16, 6077–6086 (1997).

109. Chen, H., He, Z. & Tessier-Lavigne, M. Axon guidance mechanisms: semaphorins as simultaneous repellents and anti-repellents. *Nature Neurosci.* 1, 436–439 (1998).

110. Nakamura, F., Tanaka, M., Takahashi, T., Kalb, R. G. & Strittmatter, S. M. Neuropilin-1 extracellular domains mediate semaphorin D/III-induced growth cone collapse. *Neuron* 21, 1093–1100 (1998).

111. Parker, M. W., Xu, P., Guo, H. F. & Vander Kooi, C. W. Mechanism of selective VEGF-A binding by neuropilin-1 reveals a basis for specific ligand inhibition. *PLoS ONE* 7, e49177 (2012).

112. Geretti, E., Shimizu, A., Kurschat, P. & Klagsbrun, M. Site-directed mutagenesis in the B-neuropilin-2 domain selectively enhances its affinity to VEGF165, but not to semaphorin 3F. *J. Biol. Chem.* 282, 25698–25707 (2007).

113. Miao, H. Q. et al. Neuropilin-1 mediates collapsin-1/ semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. *J. Cell Biol.* 146, 233–242 (1999).

114. Parker, M. W., Guo, H. F., Li, X., Linkugel, A. D. & Vander Kooi, C. W. Function of members of the neuropilin family as essential pleiotropic cell surface receptors. *Biochemistry* 51, 9437–9446 (2012).

115. Janssen, B. J. et al. Neuropilins lock secreted semaphorins onto plexins in a ternary signaling complex. *Nature Struct. Mol. Biol.* 19, 1293–1299 (2012).

116. Siebold, C. & Jones, E. Y. Structural insights into semaphorins and their receptors. *Semin. Cell Dev. Biol.* 24, 139–145 (2013).

117. Vadasz, Z. et al. The involvement of immune semaphorins and neuropilin-1 in lupus nephritis. *Lupus* 20, 1466–1473 (2011).

118. Hitomi, Y. et al. Human CD72 splicing isoform responsible for resistance to systemic lupus erythematosus regulates serum immunoglobulin level and is localized in endoplasmic reticulum. *BMC Immunol.* 13, 72 (2012).

119. Takagawa, S. et al. Decreased semaphorin3A expression correlates with disease activity and histological features of rheumatoid arthritis. *BMC Musculoskelet Disord.* 14, 40 (2013).

120. Williams, A. et al. Semaphorin 3A and 3F: key players in myelin repair in multiple sclerosis? *Brain* 130, 2554–2565 (2007).

121. Ieda, M. et al. Sema3a maintains normal heart rhythm through sympathetic innervation patterning. *Nature Med.* 13, 604–612 (2007).

122. Catalano, A. et al. Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function. *Blood* 107, 3321–3329 (2006).

123. Nakagawa, Y. et al. Identification of semaphorin 4B as a negative regulator of basophil-mediated immune responses. *J. Immunol.* 186, 2881–2888 (2011).

124. Gautier, G. et al. The class 6 semaphorin SEMA6A is induced by interferon-γ and defines an activation status of langerhans cells observed in pathological situations. *Am. J. Pathol.* 168, 453–465 (2006).

125. Xie, G. et al. Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. *Arthritis Rheum.* 65, 2457–2468 (2013).

126. Delaire, S. et al. Biological activity of soluble CD100. II. Soluble CD100, similarly to H-SemaIII, inhibits immune cell migration. *J. Immunol.* 166, 4348–4354 (2001).

127. Zhu, L. et al. Disruption of SEMA4D ameliorates platelet hypersensitivity in dyslipidemia and confers protection against the development of atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.* 29, 1039–1045 (2009).

128. Czopik, A. K., Bynoe, M. S., Palm, N., Raine, C. S. & Medzhitov, R. Semaphorin 7A is a negative regulator of T cell responses. *Immunity* 24, 591–600 (2006).

129. Walzer, T., Galibert, L., Comeau, M. R. & De Smedt, T. Plexin C1 engagement on mouse dendritic cells by viral semaphorin A39R induces actin cytoskeleton rearrangement and inhibits integrin-mediated adhesion and chemokine-induced migration. *J. Immunol.* 174, 51–59 (2005).

DATABASES
ClinicalTrails.gov: http://www.clinicaltrials.gov/
NCT01764737

ALL LINKS ARE ACTIVE IN THE ONLINE PDF

177